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ABBREVIATIONS USED 
 
6-OHDA 6-hydroxydopamine 
11C-DTBZ 11C-(+)-α-dihydrotetrabenazine 
18F-DOPA 3.4-dihydroxyphenylalanine marked with radioactive fluorine 
125I-GDNF glial cell line-derived neurotrophic factor marked with 
radioactive iodine 
AADC aromatic L-amino acid decarboxylase 
ALDH  aldehyd dehydrogenase 
ARTN artemin 
BDNF brain derived neurotrophic factor 
BH4 6-tetrahydrobiopterin 
bHLH basic helix-loop-helix 
cAMP cyclic adenosine monophosphate  
CDNF conserved dopamine neurotrophic factor 
CNS central nervous system 
COMT catechol-O-methyltransferase 
DA dopamine 
DOPAC 3.4-dihydroxyphenylacetic acid 
EGFR epidermal growth factor receptor 
En-1 engrailed-1 
ER endoplasmic reticulum 
ES embryonic stem cells 
ETF  epidermal growth factor receptor transcription factor  
Fgf8 fibroblast growth factor 8 
FMTC familial medullary thyroid carcinoma 
GABA gamma-amino butyric acid 
GAG glycosaminoglycan 
GDNF glial cell line-derived neurotrophic factor 
GFL GDNF family ligand 
GFRα GFL receptor α 
gp130 glycoprotein 130 
GPe external pallidum 
GPi internal pallidum 
GPI glycophospatidylinositol 
GRB2 growth factor receptor-bound protein 2 
IL-6 interleukin 6 
HS heparan sulphate 
HVA homovanillic acid 
JNK Jun N-terminal kinase 
L-DOPA L-3.4-dihydroxyphenylalanine 
LAR leukocyte common antigen-related protein 
LIF leukemia inhibitory factor 
LIFR LIF receptor 
LRRK2 leucine-rich repeat kinase 2 
MANF mesencephalic astrocyte-derived neurotrophic factor 
MAO monoamine oxidase 
Mash-1 mammalian homologues of achaete-scute 1 
MEN multiple endocrine neoplasia 
MPDP+ 1-methyl-4-phenyl-2.3-dihydropyridinium 
MTC medullary thyroid carcinoma 
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NAG N-acetyl glucosamine 
NCAM neural cell adhesion molecule 
NEC1/NEC2 proprotein convertase 1 / proprotein convertase 2 
NGF nerve growth factor 
NMDA N-methyl-D-aspartate 
NT-3 neurotrophin-3 
NT-4/5 neurotrophin-4/5 
NRTN neurturin 
Nurr1 Nuclear receptor related 1 
PC7 proprotein convertase 7 
PD Parkinson's disease 
PDGFs platelet derived-growth factors 
PET positron emission tomography 
PINK-1 PTEN-induced putative kinase 1 
PKA protein kinase A 
PNGase F peptide N-glycosidase F 
PSPN persephin 
PTPRJ receptor-type protein tyrosine phosphatise J 
RET rearranged during transfection 
ROS reactive oxygen species 
SHC Src homology 2 domain-containing protein 
SKI1 subtilisin/kexin isozyme 1 
Shh sonic hedgehog 
SNc substantia nigra pars compacta 
SNr substantia nigra pars reticolata 
SOS sucrose octasulphate 
Sox Sry-related HMG box 
SPCs  subtilisin-like proprotein converetases 
STN subthalamic nucleus 
TGFβ transforming growth factor β 
TH tyrosine hydroxylase 
Trk tropomyosin-related kinase 
UCH-L1 ubiquitin carboxy-terminal hydrolase L1 
UDP-GlcNAc uridine diphosphate N-acetyl glucosamine 
VTA ventral tegmental area 
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Post translational modifications in the GDNF molecule: functional characterization 
 
La malattia di Parkinson è caratterizzata dalla degenerazione dei neuroni 
dopaminergici. Il GDNF (Glial cell line Derived Neurotrophic Factor) è stato scoperto 
inizialmente per le sue proprietà neurotrofiche su neuroni dopaminergici e, nonostante 
le sue funzioni anche esterne al sistema nervoso centrale, l’interesse clinico si è 
concentrato sul suo potenziale nel trattamento della mallatia di Parkinson. È stato 
dimostrato che il GDNF ha effetti protettivi e neurorestorativi in diversi modelli animali 
di Parkinson e questa molecola ha inoltre mostrati risultati promettenti in due trial 
clinici su tre. 
Il GDNF appartiene alla famiglia dei GFL (GDNF Family Ligands). Gli altri membri 
della famiglia sono neurturina, artemina e persefina. In presenza dei corecettori GFRα1-
4 (GDNF Family Receptor), i GFL possono attivare il recettore tirosin chinasico RET 
(Rearranged during Transfection). Il GDNF segnala preferenzialmente attraverso il 
corecettore GFRα1. 
A causa dell’interesse terapeutico, gran parte della ricerca si è focalizzata su 
come viene formato il complesso recettoriale, dove sono espresse le varie componenti e 
quali cascate intracellulari vengono attivate da RET. Al contrario, si sa molto poco su 
come il GDNF è sintetizzato, trasportato e degradato. Il GDNF è sintetizzato come una 
preproproteina, ed è stato determinato l’N-terminale della proteina matura, che viene 
secreta. La molecola è anche stata cristallizzata: è dimerica, con sette ponti cisteinici. 
È anche ben documentato che il GDNF è N-glycosylato, ma i dettagli e il ruolo di questa 
glycosylazione non sono stati studiati. 
In questo lavoro ho eseguito un’analisi computazionale delle potenziali modifice 
post traduzionali nel GDNF in diverse specie, e ho anche comparato i quattro membri 
della famiglia dei GFL. I due potenziali siti di N-glycosylazione sono conservati nei 
mammiferi, negli uccelli, in Xenopus e nei pesci. Il primo sito di N-glycosylazione si sul 
primo “dito” della molecola, vicino a residui coinvolti nel legame al recettore, e perciò 
potrebbe essere coinvolto nella specificità della molecola per il GFRα1. Il secondo sito si 
trova vicino al “polso”, fra le due “dita”. È interessante notare come tutti i GFL (tranne 
la persefina che è il membro più divergente della famiglia) abbiano un potenziale sito di 
taglio da parte della furina nella stessa regione. 
Ho preparato mutanti a cui mancava il primo sito di glycosylazione o sia il primo 
che il secondo sito, mentre varianti con la mutazione del solo secondo sito, del sito di 
taglio della furina o di entrambi questi due ultimi siti erano già stati sintetizzati. 
Ho analizzato le diverse varianti dopo averle fatte esprimere in cellule CHO, 
usando Western blot con anticorpi anti-GDNF. L’analisi dell’espressione del GDN in 
presenza o assenza di tunicamycina rivela che solo il primo dei due potenziali siti di N-
glycosylazione è in uso. Comunque saggi di fosforilazione di RET mostrano che questo 
sito non cambia la specificità del GDNF nei confronti dei diversi GFRα: la glycosylazione 
su questo sito sembra influire maggiormente sul processamento della proteina, che è 
apparentemente secreta  come proGDNF e in quantità minore (mentre l’ammontare di 
proteina intracellulare è comparabile con quello del GDNF wild type). In realtà, in 
questo caso il livello di fosforilazione di RET è più basso di quello indotto dal wild type, 
ma questo non è causato dalla mancanza di glycosylazione. Ho anche prodotto infatti un 
mutante sul primo sito di glycosylazione che manca della sequenza pro: in questo caso la 
fosforilazione di RET era allo stesso livello di quella indotta dal wild type, nonostante 
l’ammontare di questa variante di GDNF nel medium fosse ancora minore rispetto a 
quella del mutante sul primo sito di N-glycosylazione con la sequenza pro. 
È difficile dire quanto la mancanza di glycosylazione influenzi la stabilità di questi 
mutanti, a causa del fatto le la loro quantità nel medium è minore rispetto a quella del 
wild type, ma è comunque possibile vedere che questi mutanti sono più stabili rispetto 
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al GDNF ricombinante prodotto in E. coli, che manca sia di glycosylazione che di 
sequenza pro, che è stato usato nei trials clinici. 
Il sito di taglio da parte della furina si trova immediatamente dopo l’α-elica e 
secondo le analisi computazionali è conservato nei mammiferi, uccelli e nello Xenopus. 
Comunque questo sito sembra non essere in uso durante la secrezione della molecola, 
poiché quando il GDNF è coespresso in cellule CHO insieme alla furina (sia full-lenght 
che solubile), solo le bande che si pensa corrispondano al proGDNF (glycosylato e non); 
inoltre non si osservano differenze fra il GDNF wild type e il mutante sul sito previsto di 
taglio della furina. Gli stessi risultati sono stati ottenuti quando il GDNF è stato digerito 
con furina commerciale. 
Il sito sembra non essere in uso anche quando il GDNF si lega al complesso recettoriale, 
infatti sia la durata che i livelli di fosforilazione indotti dal mutante sul sito furinico sono 
gli stessi di quelli indotti dal wild type. 
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Post translational modifications in the GDNF molecule: functional characterization 
 
Parkinson’s disease is characterised by a degeneration of dopaminergic neurons. 
The glial-cell-line-derived neurotrophic factor (GDNF) was first discovered as a 
neurotrophic factor for dopaminergic neurons and, in spite of its functions also outside 
the central nervous system, the clinical interest in this protein has focused on the 
potential of GDNF in the treatment of Parkinson’s disease. GDNF has been shown to have 
protective and neurorestorative effects in several animal models of the Parkinson’s 
disease, and GDNF has also showed promising results in two out of three clinical trials. 
GDNF belongs to the GDNF family ligands (GFLs). The other members of this 
family are the highly homologous neurturin, artemin and persephin. In the presence of 
the co-receptors GDNF family receptors α 1-4 (GFRα1-4) the GFLs can activate the 
receptor tyrosine kinase RET (REarranged during Transfection). GDNF signals 
preferentially through GFRα1. 
Due to the clear clinical interest in GDNF, a lot of research has focused on how 
the receptor complex is formed, where the ligand-receptor components are expressed, 
and what intracellular signalling cascades as well as biological functions RET mediates. 
On the contrary, very little is known on how GDNF is synthesised, transported and 
degraded. GDNF is synthesised as a preproprotein, and the N-terminus of the secreted 
mature protein has been determined. The crystal structure of GDNF shows that the 
protein is dimeric, with seven cystein bridges. It is also well documented that GDNF is N-
linked glycosylated, but the details and role of this glycosylation has not been studied.  
In this study I have made a computational mapping of the potential post-
translational modifications in GDNF from different species. I have also compared the 
four human GFLs. I have found that the two potential N-linked glycosylation sites in 
GDNF are conserved in mammalian, birds and frog. The first of the glycosylation sites is 
located close to the receptor-binding finger tip, and may therefore be involved in 
restricting the specificity of GDNF to GFRα1. The second glycosylation site is located 
adjacent to the “hinge” region, between the two receptor-binding “finger structures”. 
Interestingly all the human GFLs (except persephin, which is however the most divergent 
member of the family) harbour a potential furin cleavage site in the same hinge region.  
I prepared GDNF mutants which lack the first predicted glycosylation site or both 
the first and the second sites, while variants lacking the second glycosylation site, the 
furin cleavage site, or both the second glycosylation site and the furin site had already 
been synthesized.  
I have analyzed the variants after expression in CHO cells, using Western blotting 
with anti-GDNF antibodies. Expression analysis in the presence or absence of 
tunicamycin shows that only one of the two potential glycosylation sites is in use. This 
site is close to the receptor binding finger tip. However, the results from RET 
phosphorylation assays show that this glycosylation site does not change the specificity 
of GDNF with regard to the different GFRα receptors: glycosylation on the first site 
seems to affect mainly the processing of the protein which is apparently secreted in its 
proform and in a lower amount (while its quantity inside the cell is comparable to the 
one of wild type GDNF). In this case, actually, the phosphorylation level of RET is lower 
than the one obtained with wild type, but this is not caused by lack of glycosylation or 
amount of GDNF in the medium: when a mutant on the first glycosylation site lacking 
the prosequence was created, levels of RET phosphorylation were the same as the ones 
induced by wild type, despite the amount of this GDNF variant in the medium being even 
lower than the amount of the mutant on the first glycosylation site. 
It is difficult to tell how much the stability of these mutants is affected by the lack of 
glycosylation, since their amount in the medium is much lower than the amount of wild 
type, but still it is possible to see that these variants are still more stable than 
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recombinant GDNF produced in E. coli which lacks both glycosylation and prosequence 
and that has been used in clinical trials. 
The putative furin cleavage site is located immediately after the α-helix and 
according to computational analysis it is conserved in mammals, birds and X. laevis. 
However this site seems not to be in use during secretion, since when wild type GDNF 
was coexpressed with either full-length or soluble furin only the bands that are thought 
to correspond to proGDNF (either glycosylated or not) were affected; moreover no 
differences were observed between wild type GDNF and a variant with mutation of the 
putative furin cleavage site. The same results were obtained when digestion with 
commercial furin was performed. 
The furin site in not in use even when GDNF binds to the GFRα-RET complex, since both 
the duration and the amount of phosphorylation induced by this mutant are the same as 
the ones induced by wild type. 
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Parkinson's disease 
 
Locations of Parkinson's disease-related lesions 
 Parkinson's disease (PD) is a neurodegenerative disease that is, according to the 
classical view, characterized by the loss of dopaminergic neurons projecting from the 
substantia nigra pars compacta to the striatum. It affects the human central, peripheral 
and enteric nervous system, and progresses during time. Its diagnosis is very difficult 
and usually requires a post-mortem verification, despite the characteristic symptoms of 
the disease.1 Moreover, these symptoms appear only in a late stage, when the majority 
of the dopaminergic neurons have deteriorated. 
 PD progression can be divided in six stages, and in each of them there is the de-
velopment of characteristic inclusions named Lewy bodies and of Lewy neurites. Lewy 
neurites are composed by abnormally phosporylated neurofilaments, while Lewy bodies 
are aggregates of proteins containing misfolded α-synuclein fibrils together with other 
proteins such as ubiquitin. α-synuclein is usually located in the axon and in the presinap-
tic buttons, it is soluble but usually binds to membranes with a high affinity. Sometimes, 
and the reason why is still under research, α-synuclein loses its affinity with the mem-
branes and takes on a β-sheet conformation and aggregates with similarly misfolded α-
synuclein molecules, ubiquitin, syniphilin-1 and phosporylated neurofilaments, forming 
Lewy bodies. It remains unclear why cells fail to eliminate the misfolded α-synuclein 
with ubiquitination and proteasome recycling.2 
 Lewy bodies can be found not only in PD, but also in amyotrophic lateral sclerosis, 
Hallervorden-Spatz disease and multiple system atrophy. However, in PD, Lewy bodies 
and Lewy neurites are markers present in specific cell types at predisposed sites.3 Some 
cells affected by PD are the neuromelanin-containing projection cells in the pars com-
pacta of the subtantia nigra, the neurons of the basal nucleus of Meynert, of the tran-
senthorinal region, and in the deep layers of the anterior cingulate areas (see Figure 1).4 
Later post mortem studies have shown that the earliest Lewy bodies form in the olfac-
tory bulb, in the anterior olfactory nucleus, lipofuscin-containing projection cells of the 
dorsal IX/X motor nucleus and dorsal IX/X pigmented nucleus, of the intermedial reticu-
                                                 
1 Braak H. & Braak E., Pathoanatomy of Parkinson's disease, J Neurol (2000) 247: II/3-II/10 
2 Braak H. et al., Stages in the development of Parkinson's disease-related pathology, Cell Tissue Res 
(2004) 318: 121-134 
3 Del Tredici K. et al., Where does Parkinson Desease Pathology Begin in the Brain?, Journal of Neuropa-
thology and Experimental Neurology (2002) 61: 413-426 
4 Braak H. & Braak E., Pathoanatomy of Parkinson's disease, J Neurol (2000) 247: II/3-II/10 
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late zone and in melanoneurons of the coeruleus-subcoeruleus complex. These are fol-
lowed by the lipofuscin-containing nerve cells of the dorsomedial nucleus of the solitary 
tract, gigantocellular nucleus of the reticular formation, and caudal Raphe group. This 
study also showed that the affection of the A6/A7 melanin-laden nerve cells not only ex-
ceeds but also precedes that of the substantia nigra (see Figure 2), therefore we can say 
that the classical view is somehow incomplete. 5 
 Not all neurons develop these pathologic aggregates, in fact PD does not affect 
somatosensory and viscerosensory areas of the brain (except for olfactory structures): 
the neuron degeneration is thus in areas related to somatomotor and visceromotor func-
tions and to the limbic system. The susceptible cell types have a very long and thin axon 
(if compared to the size of their somata) and this is also poorly myelinated or unmyeli-
nated. This means that for example the small pyramidal cells of the II and IV cortical 
layer are protected and will not degenerate during the progression of the disease. This is 
probably due to the fact that less energy is needed to transmit impulses along a myeli-
nated axon; moreover these neurons are less susceptible to pathological sprouting be-
cause the axon interacts with oligodendroglial cells.6 
  
 
                                                 
5 Del Tredici K. et al., Where does Parkinson Disease Pathology Begin in the Brain?, Journal of Neuropa-
thology and Experimental Neurology (2002) 61: 413-426 
6 Braak H. et al., Stages in the development of Parkinson's disease-related pathology, Cell Tissue Res 
(2004) 318: 121-134 
 
 
 
Figure 1. Parkinson disease-
related lesions as seen in 
immuno-reactions against α-
synuclein. 
A. Neuromelanin-containing 
projection cells in the 
substantia nigra. 
B. Nucleus of Meynert 
C. Magnification of part of B 
at a higher resolution 
D. Transenthorinal region. 
The superficial layers 
contain a very dense 
network of Lewy neurites, 
and these are the layer 
projecting to the limbic 
system. 
E. Anterior cingulate area. In 
this case the damaged 
neurons are in the deepest 
cortical layers. 
From Braak & Braak (2000) 
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Figure 2. Lesions caused by Parkinson Disease detected using α-synuclein immunoreactions. 
A. Overview of the dorsal IX/X complex . Arrowheads indicate Lewy neurites, arrows indicate Lewy bodies and open 
arrowheads indicate Lewy neurites within intramedullary axons of the vagus nerve. 
B. Large visceromotor neuron of the dorsal motor nucleus containing both Lewy neurites (arrowhead) and Lewy bodies 
(arrow). 
C. The inferior salivatory nucleus constitutes the rostral continuation of the dorsal motor nucleus and displays isolated 
Lewy neurites (arrowheads) and/or Lewy bodies (arrow). 
D. α-synuclein inclusion bodies (arrowheads) in the lateral fringe subnucleus of the dorsal IX/X pigmented nucleus. 
E. The cells in the area postrema are free of lesions. Arrows indicate Lewy bodies and arrowheads Lewy neurites. 
F, G. In the mildest cases, the lesions in the dorsal IX/X motor nucleus are asymmetrical and can consist of a single 
Lewy neurite. 
H. Lewy neurites (arrowheads) in the intermediate reticular zone. 
J, K. The arrow indicates a Lewy body in a non-melanized projection cell of the intermeduate reticular zone. 
Arrowheads indicate Lewy neurites. 
Scale bar in (B) applies to (G). Scale bar in (J) also is valid for (A,C, E, F, and H). 
dmo = dorsal IX/X motor nucleus; lfr = lateral fringe subnucleus; isa = inferior salivatory nucleus; dpi = dorsal IX/X 
pigmented nucleus; arp = area postrema; irz = intermediate reticular zone. 
From Del Tredici K. & al. (2002) 
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Organization of the motor system and the limbic system 
 Every moment we receive visual, auditory and somatosensory inputs that reach 
our thalamus (respectively corpus geniculatum laterale, corpus geniculatum mediale 
and the ventral posterior complex). Thalamus sends these inputs to the primary sensory 
fields of the neocortex, and from there they reach, in order, secondary sensory fields, 
sensory association areas, prefrontal association areas, premotor fields and the primary 
motor field, giving eventually rise to a somatomotor output. We receive also viscerosen-
sory inputs, and the visceromotor reactions generate from the processing of these inputs 
in the bulbar and spinal autonomic nuclei.7 
 These inputs are filtered, so that only the most important information (and not 
the “background noise”) can reach the cortex. The information is then processed not 
only by the areas listed above, but also by the limbic centres, the striatal centres and 
the cerebellum. Actually, from the sensory association areas the information reaches 
both the prefrontal association areas and the limbic centres, entering this loop through 
the enthorinal territory and the lateral nucleus of the amygdala. This nucleus, together 
with the central amygdala, integrates exteroceptive sensory data with enteroceptive 
stimuli from autonomic centres. From the limbic loop the inputs are sent to the hypo-
thalamus (and from there to the endocrine system), to diffusely projecting non-thalamic 
nuclei, to the bulbar and spinal autonomic nuclei and to the prefrontal association ar-
eas. Thus, the limbic loop regulates the way our body reacts to viscerosensorial inputs 
and affects the prefrontal association areas. It is important to notice that these prefron-
tal areas are connected to the sensory association areas both directly and indirectly (via 
the limbic loop).8  
In order to perform correctly a movement the striatal loop and the cerebellar 
loop are very important. The informations enter the striatal loop at the dorsal striatum 
and exit from the internal pallidum and the substantia nigra pars reticulata, reaching 
the ventral anterior thalamic nucleus that projects to areas of the cortex involved in 
movements. The route from the afferent nuclei to the efferent ones can be both direct 
and indirect. The direct route is facilitatory, whereas the indirect route is inhibitory: the 
cortex projects to the striatum that is GABAergic and projects to the internal pallidum 
and to the substantia nigra pars reticulata (both GABAergic). Internal pallidum and sub-
stantia nigra pars reticulata are efferent nuclei and project to the thalamus that is exci-
tatory on the cortex. The result of these two inhibitions is facilitation on thalamus, so 
                                                 
7 Braak H. & Braak E., Pathoanatomy of Parkinson's disease, J Neurol (2000) 247: II/3-II/10 
8 Ibid. 
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the direct route is facilitatory. The striatum projects also to the external pallidum which 
is GABAergic and projects to the subthalamic nucleus (glutamatergic), projecting to the 
efferent nuclei. This time there is a resulting facilitation on the subthalamic nucleus, 
which activates the efferent nuclei, eventually inhibiting the thalamus (see Figure 3). 
It is very important to maintain the correct balance between these two routes in 
order to perform correct movements. In PD this balance is lost and this causes problems 
to the movement. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Also cerebellum plays an important role in controlling the movements. It receives 
informations from the spinocerebellar tract, the vestibular nerve and the inferior olive; 
these are processed so that the cerebellum can control equilibrium, eye and head 
movements and also regulate movements so that they are commensurate with their aim. 
 It is then possible to summarize the importance of these three loops in a scheme 
such as the one in Figure 4. The damaged regions are coloured in red: the darker is the 
colour, the more severe is the lesion. 
Figure 3. Organization of the basal ganglia. The cortex projects to the striatum that is GABAergic and projects to the 
internal pallidum and to the substantia nigra pars reticolata (both GABAergic). GPi and SNr are efferent and project 
to the thalamus that is excitatory on the cortex. Since we have two inhibitions there is a facilitation on thalamus, so 
the direct route is facilitatory. 
The striatum projects also to the external pallidum (GABAergic) that projects to the subthalamic nucleus 
(glutamatergic), projecting to the efferent nuclei. This time we have two inhibitions (striatum and GPe) that are 
facilitatory on the subthalamic nucleus, that activates the efferent nuclei, eventually inhibiting the thalamus. 
Abbreviations: GPe = external pallidus, GPi = internal pallidus, SNc = substantia nigra pars compacta, SNr = substantia 
nigra pars reticolata, VTA = ventral tegmental area. 
From Martin JH., Neuroanatomy, text and atlas, McGraw-Hill, 2003 
 Introduction – Parkinson’s disease 
7 
 
 
 
 
 
 
 
 
 
 
Symptoms 
 PD was described for the first time by James Parkinson in 1817 in his essay “An 
essay on the Shaking Palsy”. The symptoms appear when the greater part of the dopa-
minergic neurons is lost. This loss results in a decreased stimulation of the motor cortex 
and causes muscle rigidity, tremor, bradykinesia, a slowing of physical movements, and 
postural instability. 9 
 The tremor is usually the first appearing symptom, however 30% of patients do 
                                                 
9 Jankovic J., Parkinson's disease: clinical features and diagnosis, J. Neurol. Neurosurg. Psychiatr. (2008) 
79: 368–76 
Figure 4. Importance of limbic, striatal and cerebellar loop in regulating viscero- and somatomotor outputs. The 
damaged lesions are coloured in red (dark red = severe lesions, light red = less severe lesions), while the yellow big 
arrows represent in order the limbic loop, the striatal loop and the cerebellar loop. 
Abbreviations:  ant. cing. areas = anterior cingulate areas,  dors. mot. IX, X = dorsal motor area of the 
glossopharyngeal and vagal nerves, dors. striatum = dorsal striatum, hippoc. formation = hippocampal formation, 
hypoth. = hypothalamus, inf. oliv. = inferior olive, m. b. = mamillary body, magnoc. bas. forebr. = Magnocellular  
nuclei of the basal forebrain, n. ruber magno. = magnocellular portion of the nucleus ruber, n. ruber parv. = 
parvocellular portion of the nucleus ruber, nucl. sol. tr. = nuclei of the solitary tract, parabrach. nucl. = parabrachial 
nuclei,  periaqued. Grey = periaqueductal gray, prim. sens. fields = primary sensory fields, r.s. = retrosplenial region, 
raphe nucl. = raphe nuclei, SNr = substantia nigra pars reticolata, subst. nigra pars comp. = substantia nigra pars 
compacta, secondary sens. fields = secondary sensory fields, sensory assoc. areas = sensory association areas,  
spinocerebell. tract = spinocerebellar tract,  subthal. nucleus = subthalamic nucleus, thalamus nAD = anterodorsal 
nucleus of the thalamus, thalamus nMD = mediodorsal nuclei of the thalamus, thalamus nVA = ventral anterior nuclei 
of the thalamus, thalamus nVI = ventral intermediate nuclei of the thalamus, transentorh. region = transentorhinal 
region, tuberomam. nucl. = tuberomamillary nucleus, ventr. pallidum = ventral pallidum,  ventr. tegm. = ventral 
tegmentum 
Modified from Braak H. & Braak E., 2000 
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not show tremor in the beginning and it appears only later on. It affects the most distal 
parts, it's usually unilateral and it is a rest tremor: it is maximal when the limb is at rest 
and disappears during voluntary movements and sleep.10 Thus, this kind of tremor is very 
different from the one that appears, for example, in cerebellar tumour, which is maxi-
mal during movements, especially when a high coordination is needed. 
 Rigidity comes from joint stiffness and increased muscle tone and is often associ-
ated with pain. The result is a so-called “cogwheel rigidity” when the muscle is passively 
moved and is due to the loss of harmony between flexor muscles and antagonist mus-
cles. In normal conditions gamma circuit feels muscle tone and the extrapyramidal cir-
cuit (composed by basal nuclei) regulates its activity. In PD this regulation is lost and the 
subsequent increase of muscle tone causes movement problems. For example, another 
symptom is micrography and it is the consequence of increased muscle tone.11 
 Patients with PD show also slowness of movement, this is called bradykinesia; in 
the worst cases also akinesia (absence of movement) can be observed. The problem here 
is not only the execution of the movements but also its planning and initiation. In pa-
tients affected by PD there is also a phenomenon called kinesia paradoxica: it is possible 
to see that sometimes immobile patients are capable of doing rapid movements if they 
get excited. This suggests that their motor programmes could be intact, but patients 
have problems in accessing them. It has been suggested that bradykinesia is the result of 
the disruption in normal motor cortex activity caused by reduced dopaminergic function. 
In about 50% of the cases also freezing can be observed. This most commonly affects the 
legs, and the result is that the patient suddenly cannot move; freezing state is transient 
since usually the motor block lasts for less than 10 s. There are different kinds of freez-
ing: start hesitation, turn hesitation, hesitation in tight quarters, destination hesitation 
and open space hesitation. Episodes are mitigated by L-DOPA therapy and sometimes pa-
tients can use tricks to avoid freezing, such as marching to command, walking to music, 
stepping over objects, and so on.12 
 Postural instability is also shown. Patients tend to walk with short steps, with 
their feet barely leaving the ground, and with a reduced arm swinging. The trunk is 
flexed forward. There is also the failure of postural reflexes which, together with or-
thostatic hypotension, leads to falls due to impaired balance.13 
                                                 
10 Jankovic J., Parkinson's disease: clinical features and diagnosis, J. Neurol. Neurosurg. Psychiatr. (2008) 
79: 368–76 
11 Ibid. 
12 Ibid. 
13 Ibid.  
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 Secondary symptoms include language problems (for example monotonic speech 
or dysarthria), facial hypomimia, dysphagia, drooling, cognitive problems (for example 
slowed reaction time, dementia, and short term memory loss). Sleep disturbances, im-
paired proprioception, reduction of sense of smell, urinary incontinence, altered sexual 
function, constipation, hallucinations and decreased 
blink rate are also shown.14 
 At the present time, there aren't known bio-
markers or tests that can help us to recognize PD, 
since the presence of Lewy bodies and Lewy neu-
rites in specific regions of the nervous system can 
be observed only post-mortem. The only other test 
available is a PET that shows reduced uptake of 18F-
DOPA or 11C-DTBZ in the striatum (see Figure 5). 
 
Aetiology 
 PD is a multifactorial disease. This means that it may have different causes. The 
most common is idiopathic (without a known cause) PD, but it can be also caused by tox-
ins, traumas, cerebral anoxia, drugs and genetic factors (so in some cases it can be an 
inherited disease). There is also the possibility of developing an iatrogenic form of PD, 
for example some patients can develop a reversible form of PD because of the drugs 
used to cure schizophrenia. This eventually disappears when the drug treatment is sus-
pended. 
 During 1980s some heroin addicts in California consumed a street drug and devel-
oped a parkinsonism. The altered synthesis conditions of this drug lead to pH alterations 
and caused the formation of MPTP, a contaminative. å MPTP can cross the blood brain 
barrier and in the glial cells is converted by monoamine oxidase B in MPP+. This can en-
ter the dopaminergic neurons using the DA transporter and blocks the complex I of the 
mitochondrial respiratory chain leading the cell to death (see Figures 6  and 7).15   
                                                 
14 Jankovic J., Parkinson's disease: clinical features and diagnosis, J. Neurol. Neurosurg. Psychiatr. (2008) 
79: 368–76. 
15 Chiueh C. et al., In vivo generation of hydroxyl radicals and MPTP-induced dopaminergic toxicity in the 
basal ganglia, Ann N Y Acad Sci (2004) 738: 25–36 
 
Figure 5. Reduced uptake of 11C-DTBZ can be 
seen in the brain of a non-human primate 
model of PD (right) if compared to a normal 
brain (left). A reduced uptake is also visible in 
the asymptomatic model, which isn’t showing 
the symptoms yet. The areas where the 
uptake is lower are blue and green whereas 
the ones with a higher uptake are yellow and 
red. (Modified from Blesa et al., 2010) 
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Figure 7. The increased produc-
tion of reactive oxygen species 
can be due to mitochondrial im-
pairment but also to the distribu-
tion of vesicular dopamine into 
cytosol (also caused by MPP+). in 
the cytosol DA auto-oxydizes and 
generates ROS. These damage 
DNA and probably modify the ex-
pression of redox-sensitive tran-
scription factors. The damage is 
sensed by p53 that  activates and 
upregulates Bax. This is translo-
cated into the mitochondrion 
(probably by mediation of JNK) 
and induces cytochrome C release 
into the cytosol. Cytochrome C, 
with the adaptor molecule apaf1, 
activates caspase 9 that activates 
caspase 3, leading the cell to 
death. 
Modified from Vila M. & Przed-
borski S., 2003 
Figure 6. MPTP can cross the 
brain barrier and in non-
dopaminergic cells it is metabo-
lized in MPDP+ by the enzyme 
MAO-B. Then, probably by spon-
taneous oxidation, it generates 
MPP+, which has a high affinity for 
the DA transporter and enters 
dopaminergic neurons. Here, it is 
stored with an active process into 
the mitochondrion, where inter-
feres with complex I of the elec-
tron transport chain. This im-
pedes the flow of electrons and 
results in an increased production 
of free radical which causes oxi-
dative stress and activation of 
programmed cell death molecular 
pathways. 
From Vila M. & Przedborski S., 
2003 
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Since then one of the most common toxin-induced models for PD is the MPTP model. 
Other toxin-induced models are made with 6-hydroxydopamine (a toxin that kills dopa-
minergic neurons and that has been used to evaluate potential therapies such as cell 
transplantation and neurotrophic factors) or rotenone (a pesticide and herbicide).16 
 In other cases PD can derive from other illnesses, for example one of the conse-
quences of the 1918 flu pandemic was post-encephalitic parkinsonism. 
 As said before, also genetic factors may play a role in PD. Understanding which 
are the mutated genes and their functions can help also in understanding the mecha-
nisms underlying the pathogenesis of idiopathic PD. A big difference between genetic 
and sporadic PD, however, is that the onsets of the genetic forms of the disease are usu-
ally at an earlier age that the ones related to the sporadic forms. 
 The first mutation related to PD was found in a large family with Italian origins 
(known as Contursi family). In this case the disease is autosomal dominant. This muta-
tion is on the chromosome 4 and affects the gene for α-synuclein (see Figure 8), an 
abundant neuronal protein implied in the synaptic mechanisms. In this family a missense 
mutation (G209A) could be found, then other mutations on this gene were found in other 
families in Germany and Spain, and some of these mutations are responsible not only for 
PD but also for dementia with Lewy bodies and multiple system atrophy. Human α-
synuclein is a monomeric protein of 140 amino acids with a high homology grade with 
the same protein in other species. It is one of the members of the synuclein family, to-
gether with β-synuclein, γ-synuclein and synoretin and is expressed not only in neuronal 
cells but also in endothelial cell and platelets. Its biological function is still unclear: 
some hypotheses are lipid binding, inhibition of phospholipase D2, interaction with other 
proteins such as syniphilin, chaperone activity, regulation of dopamine release, inhibi-
tion of tyrosine-hydroxylase activity, control of dopamine transporter, synaptic vesicle 
transport, plasticity and/or regulation of vesicle pool. Structural changes can be caused 
by oxidative stress and/or genetic mutations, and in vitro studies have shown that mu-
tated α-synuclein increases its tendency to aggregate and generate fibrils, favours mito-
chondrial depolarization, favours apoptosis activation and inhibits proteasome activity. 17  
There is also another type of autosomal dominant PD caused by duplication or triplica-
tion of the α-synuclein gene (see Figure 8). The increase of repetitions is associated with 
                                                 
16 Hattori N. & Sato S, Animal models of Parkinson’s disease: Similarities and differences between the 
disease and models, Neuropathology (2007) 27: 479–483 
17 Farrer MJ., Genetics of Parkinson disease: paradigm shifts and future prospects, Nature (2006) 7: 306-
318 
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a more severe phenotype. 18 
 A mutation can occur also on the ubiquitin carboxy-terminal hydrolase L1 (see 
Figure 8). UCH-L1 is very abundant in the brain (2% of the soluble protein total) and the 
missense mutation C277G decreases its activity. 19 
 Another mutation can be on the parkin gene (see Figure 8). In this case PD is in-
herited as an autosomal recessive disease. Parkin gene is on chromosome 6 and the mu-
tations can be deletions, exonic duplications or triplications, point mutations, etcetera. 
Parkin protein has an ubiquitin-like domain at its N-terminus and two RING-finger do-
mains flanking a cystein enriched domain at the C-terminus. It belongs to the ubiquitin 
E3 ligase family, and is probably important for the degradation of anomalous proteins, 
but when it is mutated loses its activity and this causes an accumulation of non-
ubiquitinated proteins and this can lead to Lewy bodies formation. 20 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other mutations may affect the mitochondrial function and can be involved in 
oxidative stress. For example a mutation on the PTEN-induced putative kinase 1 (PINK-1) 
                                                 
18 Farrer MJ., Genetics of Parkinson disease: paradigm shifts and future prospects, Nature (2006) 7: 306-
318 
19 Ibid. 
20 Ibid. 
Figure 8. The mutations described above influence the proteasome pathway. In red: mutated genes affecting the 
various steps of the pathway. 
Abbreviations: U = ubiquitin, UCH-L1 = ubiquitin carboxy-terminal hydrolase L1 
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locus on chromosome 1 makes the neuron become more susceptible to oxidative stress. 
PINK-1 is a ubiquitous mitochondrial protein with a highly conserved kinase domain and 
is homologous to kinases of the calmodulin family. Its function is still unknown, but it 
seems to protect neurons from stress-induced mitochondrial dysfunction and apoptosis.21 
 Other mutations can occur on the DJ-1 locus, which is still on chromosome 1, very 
near to PINK-1 locus. The mutations can be both point mutations and deletions, also in 
the splicing sites. This protein has been found also in cytoplasmic inclusions in tau-
pathies, such as multiple system atrophy, and its role is still unclear, even if it is thought 
that it could be important for the oxidative stress response because it is localized both 
in cytoplasm and nucleus, but when oxidized translocates to mitochondria.22 
An autosomal dominant variant of PD with incomplete penetrance is caused by a 
mutation on the leucine-rich repeat kinase 2 (LRRK2) which transcript generates a pro-
tein called dardarin. This protein has two domains: a tyrosine kinase catalytic domain 
and a GTPase domain. It has been hypothesised that the mutation can cause a gain of 
function. Dardarin is a member of the ROCO protein family, is widely expressed and has 
a cytosolic location. About 10% of LRRK2 can be found in mitochondria and its suggested 
role is in cell signalling, cytoskeletal reorganization, vesicle trafficking and nucleo-
cytoplasmic transport.23 
Also α-synuclein and parkin mutation may interfere with mitochondrial function: 
in transgenic mice, α-synuclein over expression increases oxidative stress and enhances 
the toxicity of MPTP.24 Parkin can associate with the outer mitochondrial membrane, 
protecting the cell against cytochrome C release and the consequent caspase activa-
tion.25 It may also associate with mitochondrial transcription factor A and enhance mito-
chondrial biogenesis.26 Moreover, physical association have been reported between DJ-1 
and α-synuclein, DJ-1 and parkin, and DJ-1 and PINK-1 and there is evidence that DJ-1,  
PINK-1 and parkin function sequentially in the same pathway.27 
 
                                                 
21 Farrer MJ., Genetics of Parkinson disease: paradigm shifts and future prospects, Nature (2006) 7: 306-
318 
22 Ibid. 
23 Ibid. 
24 Song DD. et. al, Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein trans-
genic mice after treatment with MPTP, Exp Neurol. (2004) 186(2):109-11 
25 Darios F. et al., Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-
dependent cell death, Hum Mol Genet. (2003) 12(5): 517-26 
26 Kuroda Y. et al., Parkin enhances mitochondrial biogenesis in proliferating cells, Hum Mol Genet. 
(2006) 15(6): 883-95 
27 Lin MT. & Flint Beal M., Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases, 
Nature (2006) 443: 787-795 
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Therapy 
 Currently, all therapies available for PD are just symptomatic therapies; this 
means that they do not stop PD progression, but reduce signs and symptoms for the com-
fort of the patient. 
 
Drug treatment 
 Pharmacological approach includes dopaminergic drugs, dopaminergic agonists, 
MAOB and COMT inhibitor, amantadine, and anticholinergic drugs. 
 Dopaminergic drugs aim to maintain normal dopamine levels. Unfortunately do-
pamine itself is not able to cross the blood brain barrier, so what is normally used is its 
precursor L-DOPA. L-DOPA causes sudden improvements, but has many side effects re-
sulting from the increase of dopamine levels: nausea, vomit, postural hypotension, hal-
lucinations and dyskinesias. Moreover, this drug is administered per os and is metabo-
lized in peripheral districts, so that only a small part reaches CNS (1-3%). Usually other 
drugs are used together with L-DOPA, so that its side effects are lowered and also its 
dose can be decreased. For example the result of inhibiting peripheral dopadecarboxy-
lases is that L-DOPA remains intact for a longer time, and thus more drug reaches the 
brain (10%). Also nausea and vomit can be reduced since these are the result of the 
stimulation of the chemoreceptor trigger zone and they can be controlled with domperi-
done, an antidopaminergic drug that does not cross the blood brain barrier. However, 
after some years, the effects of L-DOPA decrease in half of the patients: they have a 
shorter duration and dyskinesias are more frequent, so, in order to delay this phase, the 
lowest possible amount of L-DOPA is always used. These complications are due to the 
fact that when the therapy begins there is still a certain percentage of dopaminergic 
neurons left, but with time the number of neurons decreases so the storage of dopamine 
becomes impossible.28  
                                                 
28 Rang HP., Dale MM., Pharmachology, Elsevier, 2007  
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 In the brain there are five types of dopamine receptors that can be divided into 
two groups: D1-like receptors enhance cAMP levels, while D2-like receptors decrease 
them (see Figure 9). All these receptors are G-coupled with seven transmembrane do-
mains and consensus sequences for phosphorylation in the second and third intracellular 
loops and in the C-terminus which is intracellular. D1 and D5 belong to D1-like receptors 
and the increase of cAMP caused by their activation leads to the activation of PKA and 
the subsequent phosphorylation of DARPP32, a protein phosphatase inhibitor that can be 
found at high levels in dopa-
minergic neurons. The main dif-
ference between D1 and D5 is that 
D5 has a higher affinity for dopa-
mine; however both regulate the 
activity of the prefrontal cortex 
and are increased in patients with 
schizophrenia. D2L, D2S, D3 and D4 
belong to the D2-like receptors. 
D2L and D2S are two isoforms of D2 
receptor originated by alternative 
splicing and the difference is that 
D2L is postsynaptic while D2S is a 
presynaptic autoreceptor. These 
receptors decrease cAMP levels 
and Ca++ channels permeability, 
and increase K+ channels perme-
ability; the difference between 
D2, D3 and D4 is in their localiza-
tion and their affinity for differ-
ent drugs. 29 Dopamine agonists are less effective than L-DOPA, but they can be used to 
reduce the dose administered. They can derive from ergot or not. Ergot derivatives are 
less used now because of their side effects, like fibrosis affecting cardiac valves. Non-
ergot drugs act on D3 receptors, determining however an excessive stimulation of other 
areas that causes hypersexuality, hallucinations, psychosis, leg edemas and sleepiness.30
  
                                                 
29 Siegel GJ. et al., Basic Neurochemistry, molecular, cellular and medical aspects, Elsevier, 2006   
30 Rang HP., Dale MM., Pharmachology, Elsevier, 2007  
Figure 9. Effects of dopamine receptor on intracellular pathways. gene 
expression. D1 and D5 receptors are coupled to adenylyl cyclase via a 
stimulatory G protein, while D2 receptor inhibits cyclase activity via 
coupling to an inhibitory G protein. Also the activation of D3 and D4 
receptors inhibits cyclase activity. Adenylyl cyclase catalyzes the 
conversion of ATP into cAMP, which causes dissociation of the 
regulatory and catalytic  
subunits of protein kinase A. This for example can phosphorylate and 
activate DARPP-32 that inhibits protein phosphatase-1. The 
phosphoproteins activated by the kinase in turn can lead to short-term 
responses within the cell or activate transcription factors which enter 
the nucleus and alter gene expression acting either directly on the 
target gene or via an immediatly early gene. 
Abbreviations: AC = adenylyl cyclase, AP-1 = adaptor protein 1, CRE = 
cAMP response element, IEG = immediately early gene, TF = 
transcription factor. 
From Siegel et al., Basic Neurochemistry, molecular, cellular and 
medical aspects, Elsevier, 2006   
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Dopamine, like norepinephrine and epinephrine, is a catecholamine. Its synthesis 
in the brain starts from tyrosine that is converted into DOPA by tyrosine hydroxylase, an 
enzyme whose activity is the limiting step for dopamine synthesis (tyrosine hydroxylase 
receives a negative feedback from dopamine: there are autoreceptors synaptic level 
that sense dopamine levels in the synaptic cleft and inhibit TH). DOPA is then trans-
formed into dopamine by DOPA decarboxylase and, in noradrenergic cells, dopamine-β-
hydroxylase turns it into norepinephrine, which can be eventually converted into epi-
nephrine by phenilethanolamine-N-methyltransferase. Dopamine is stored in acid vesi-
cles, in which is transported with the vesicle transporter V-MAT. The acidity of these 
vesicles is achieved with proton pumps and it's necessary for the catechol ring of dopa-
mine.31 
Dopamine is degraded by monoamine oxidases and catechol-O-methyltransferase 
(see Figure 10). When it is degraded by COMT, 3-methoxytyramine is formed and this is 
then converted into homovanillic acid by MAO and aldehyde dehydrogenase. The other 
possible way is that dopamine is degraded by MAO and then converted into dihydrox-
phenylacetic acid by aldehyde dehydrogenase. Eventually, COMT can turn DOPAC into 
HVA. Is it possible to measure HVA levels in urine, but it is important to consider that 
these are not the result of the CNS production only but also of the peripheral produc-
tion. 32 
 
There are many drugs interacting with the catabolic pathway of the dopamine, 
                                                 
31 Siegel GJ. et al., Basic Neurochemistry, molecular, cellular and medical aspects, Elsevier, 2006   
32 Ibid.   
Figure 10. Dopamine catabolism. DA can be converted into dihydroxyphenilacetic acid by monoamine oxydase and 
aldehyd dehydrogenase, or into 3-methoxytyramine by catechol-O-metyltransferase. This can be then converted indo 
homovanillic acid by MAO and ALDH, and also dihydrxyphenylacetic acid can be transformed into HVA by COMT. 
Abbreviations: ALDH = aldehyd dehydrogenase, COMT = catechol-O-methyltransferase, MAO = monoamine oxydase. 
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some of them interfere with MAOB and some others with COMT and all of them make 
possible to diminish the quantity of L-DOPA administered. 33  
 The degeneration of dopaminergic neurons leads also to an unbalance between 
dopamine and acetylcholine levels in the basal nuclei, thus also anticholinergic drugs are 
used. These are not very effective if compared to L-DOPA and dopaminergic agonist, but 
can be used especially in iatrogenic parkinsonism. It is a good rule not administering 
these drugs to people with cognitive problems, because they can be worsened, and 
other side effects are decreased mucus production in nose and throat (and consequent 
dry throat), urinary retention, confusion with possible hallucinations.34  
 Another drug used is the antiviral amantadine. It is used in the advanced phases 
of the disease and probably blocks glutamatergic receptors NMDA. This drug has an ef-
fect on dyskinesias caused by chronic use of L-DOPA and its side effects are confusion, 
livedo reticularis, hallucinations and nightmares.35  
 
Stem cells 
 Since the drug treatment is only symptomatic and there is the real necessity of 
blocking the disease progression (or at least interfere with it), also stem cell therapy has 
been considered. This could occur through endogenous cell recruitment or transplant. 
 In 1980 both transplant of developing dopaminergic neurons (from abortions of 7-9 
weeks) and xenotransplants (from pig) have been made. The results were interesting 
since the disease progression seemed to stop, but ten years later other studies carried 
out also with placebos have reopened the discussion: midbrain stem cells can modify the 
course of the disease, but their ability to produce dopaminergic cells is unstable and 
thus they are not and adequate source of this type of cells.36 
 In 1998 Ye W. et al. found out that DA neurons are induced by Fgf8 and Shh, and 
two years later the first TH positive mouse neurons were produced. First of all neural 
precursor cells must be produced and then these have to differentiate into dopaminergic 
neurons. In order to differentiate ES to a neural fate is it possible to use embryoid bod-
ies’ formation, retinoic acid, or other protocols. The cells are then evaluated by the 
presence of neural precursor markers such as Sox1, Sox2, βtubulin3, MAPs and neuro-
filament proteins. Then Fgf8, Shh and ascorbic acid are added to the culture and in this 
                                                 
33 Rang HP., Dale MM., Pharmachology, Elsevier, 2007  
34 Ibid.  
35 Ibid. 
36 Yong VW. et al., Transplantation of human sympathetic neurons and adrenal chromaffin cells into 
parkinsonian monkeys: no reversal of clinical symptoms, J Neurol Sci. (1989) 94:51-67 
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way is it possible to detect TH in over 30% of the neurons. Later this proportion has been 
increased using a cocktail containing survival promoting factors such as interlukin-1β, 
GDNF, neurturin, TGFβ3 and dibutyryl-cAMP: these factors enhance RNA expression levels 
of En-1, Mash-1, dopamine receptor 2, TH and Nurr1.37 
 However, transplantation of human DA neurons obtained from embryonic stem 
cells in animal models has also shown poor survival levels; these need to be increased 
for a clinical application.38 
 Another of the observations that can be made is that transplanted cells can re-
place the degenerated ones, but do not solve the problem at its roots since the disease 
progression is not stopped.39 
 
Gene therapy 
 Another approach can be transplant cells modified to produce higher levels of 
neurotrophic factors with neuroprotective effects, such as GDNF, or more enzymes in-
volved in dopamine metabolism. However, as said earlier, this approach presents the 
problem of cell survival and of their stability.40 
 An alternative approach could be the use of viral vectors to deliver those genes 
directly into neurons. The delivered genes could be involved in DA metabolism, in neu-
roprotection or in inhibition of brain nuclei that become overactive in PD.41 
 Viral vectors encoding for TH have been used, resulting in a long term expression 
of tyrosine hydroxylase and some corrections of behavioural deficits. However it was 
used a partial-lesion 6-OHDA model, meaning that there was still some endogenous TH 
activity left, so it is impossible to determine the exact amount of dopamine produced by 
the delivered tyrosine hydroxylase. Nevertheless these studies provided proof-of-
principle that the use of TH delivered with viral vectors improved the symptoms.42 
 Tyrosine hydroxylase needs a cofactor called BH4, so also the cotransfection with 
TH and guanosine triphosphate cyclohydrolase I (the limiting enzyme for the synthesis of 
BH4) has been tested. The results were better than the ones of transfection with tyro-
                                                 
37 Maxwell SL. & Li M., Midbrain dopaminergic development in vivo and in vitro from embryonic stem 
cells, J Anat. (2005) 207(3):209-18 
38 Lindvall O., Kokaia Z., Stem cells for the treatment of neurological disorders, Nature. (2006) 
441(7097):1094-6 
39 Ibid. 
40 Lawlor PA. & During MJ., Gene therapy for Parkinson’s disease, Expert Rev Mol Med. (2004) 6:1-18 
41 Ibid. 
42 Ibid. 
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sine hydroxylase only.43 
 Also viral vectors encoding AADC have been used to increase dopamine levels. 
Transduction of these vectors together with exogenous L-DOPA lead to an increase in do-
pamine levels higher than the one due to only L-DOPA administering. This is interesting 
as it makes possible a reduction of L-DOPA used in therapy, and a consequent diminution 
of side effects.44 
 Moreover, loss of dopaminergic neuron leads to an increased activity of the exci-
tatory neurons of the subthalamic nucleus resulting in an increase of inhibition on 
thalamus and downstream motor pathways. It has been proposed that silencing of STN 
could result in an improvement of symptoms, and actually electrical inhibition, ablation 
or pharmacological silencing of the subthalamic nucleus have all been reported to con-
trol PD symptoms. So delivery into the STN of glutamic acid decarboxylase, the enzyme 
involved in the synthesis of GABA, of parkinsonian rats has been tested and it has given 
proof-of-principle of the improvement of the symptoms.45  
 One of the main issues of gene delivery, however, is regulation of gene expression, 
as over-expression of delivered genes may result in a series of undesired side effects. 
Inducible systems are being developed, but at the present time they are still leaky or 
poorly inducible in vivo.46 
 
Neurotrophic factors 
 Neurotrophic factors could be very useful for PD, in different ways. First of all 
they can promote survival of subpopulations of neurons exposed to MPTP or 6-OHDA in 
models of PD; so, if toxin induced death shares any mechanism with the pathogenesis of 
PD, neurotrophic factors could slow or stop dopaminergic degeneration. Second, they 
could restore functions of neurons that are losing their phonotype and are losing their 
capacity of synthesizing dopamine. Third, some neurotrophic factors have effects on cell 
excitability and could stimulate the dopaminergic system. Last, it can be that in some 
cases PD is caused by loss of neurotrophic factors or disruption in their signalling cas-
cades, thus a therapy could be replacing the missing factors.47 
 Hence the idea of using neurotrophic factors for therapy. GDNF was administered 
                                                 
43 Ibid. 
44 Lawlor PA. & During MJ., Gene therapy for Parkinson’s disease, Expert Rev Mol Med. (2004) 6:1-18 
45 Ibid. 
46 Ibid. 
47 Peterson AL. & Nutt JG., Treatment of Parkinson's disease with trophic factors, Neurotherapeutics. 
(2008) 5(2):270-80 
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by monthly intraventricular injections, but, while the results in animal models were 
good, in humans it had no effect. This was probably due to the route of delivery and to 
the fact that switching from an animal model to a human the tissue volume increases, so 
the diffusion of the neurotrophic factor is affected. Also relevant side effects were 
shown, probably for the diffusion of GDNF in the cerebrospinal fluid that caused its act-
ing on structures with GDNF receptors but not involved in movement. Thus GDNF was 
administered by chronic infusion using pumps in the postero-dorsal putamen. The side 
effects were limited, and no nausea and vomit were observed. After three months of 
GDNF infusion the symptoms improved, and after six months periods of severe immobil-
ity were completely eliminated and also 18F-DOPA uptake was increased.48 This was a 
phase I trial, but sadly a phase II trial did not confirm the results since there weren't sig-
nificant differences between patients receiving the neurotrophic factor and the control 
group.49 However, other studies have hypothesized that this discrepancy in results may 
be explained in terms of bioavailability of GDNF: applying the protocol from trial phase 
II, 125I-GDNF was unevenly distributed in the putamen of parkinsonian monkeys. It was 
found mainly around the catheter tip with its concentration decreasing exponentially as 
the distance from the tip increased and as a result its bioavailability was limited to 2-9% 
of the putamen. Thus, even if further studies are required, probably the different re-
sults may be explained with the different protocol and catheter used in phase II trial.50 
 Also neurotrophic factors can be delivered with viral vectors: adenovirus, lenti-
virus and adenoassociated virus have been used to introduce GDNF into brain tissue and 
it affected positively both behaviour and nigrostriatal innervation levels.51 
Other studies have been carried out with neurturin on cell cultures. This molecule 
is from the same family as GDNF and was delivered with lentiviral vectors. Wild type 
neurturin had no effect because it was secreted in its pro-form, so other variants of 
neurturin were considered. Deletion of the pro-region resulted in significantly higher se-
cretion of active NRTN, which was further increased when the signal peptide was substi-
tuted with the immunoglobulin heavy-chain signal peptide. This was reproduced in vivo 
in lentiviral-transduced rat striatal cells and enabled efficient neuroprotection of dam-
aged nigral DA neurons, similar to GDNF. So this is an interesting option that should be 
                                                 
48 Gill SS. et al., Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease, 
Nat Med. (2003) 9(5):589-95 
49 Lang AE. et al., Randomized Controlled Trial of Intraputamenal Glial Cell Line–Derived Neurotrophic 
Factor Infusion in Parkinson Disease, Ann Neurol (2006) 59: 459-466 
50 Salvatore MF. et al., Point source concentration of GDNF may explain failure of phase II clinical trial, 
Exp Neurol. (2006) 202(2):497-505 
51 Lawlor PA. & During MJ., Gene therapy for Parkinson’s disease, Expert Rev Mol Med. (2004) 6:1-18 
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considered.52 
 In other studies BDNF, which is required for the developing of the correct number 
of neurons in the substantia nigra, has been used. It is expressed by DA neurons both in 
the SNc and VTA and, at lower concentrations, in the striatum. In post-mortem samples 
both BNDF and BDNF mRNA levels were lower in patients with PD than in controls. Fibro-
blasts secreting BDNF have been implanted near the substantia nigra of rats that were 
later treated with MPP+, and death of neurons was 86% lower than in controls. Con-
versely, the knock-down of BDNF receptor turned out in a decreased number of neurons 
in the SNc, accumulation of α-synuclein, and reduced TH activity in the striatum.53 
                                                 
52 Fjord-Larsen L. et al., Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene 
transfer of a modified Neurturin construct, Exp Neurol. (2005) 195(1):49-60 
53 Peterson AL. & Nutt JG., Treatment of Parkinson’s Disease with Trophic Factors, Neurotherapeutics. 
(2008) 5(2):270-80 
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GDNF, its receptor complex and signalling 
 
What are neurotrophic factors? 
 A short definition could be that neurotrophic factors are molecules involved in 
neuron growth and survival, however it is not easy to tell exactly what a neurotrophic 
factor is: there are also some inorganic molecules that promote neuron survival, such as 
potassium at high concentrations.54 Moreover many molecules known as neurotrophic 
factors act also outside the CNS, so this definition is somehow incomplete. In 1988 some 
criteria to define a neurotrophic factor were proposed. First of all it keeps alive neurons 
that would die in its absence, second it has to be present in its active form, synthesized 
and secreted by the target tissue of the those neurons, third its amount in the target tis-
sue must be very low, and fourth it affects development and maintenance of neurons in 
vivo.55 
 At the beginning of the development of the central nervous system there are 
more neurons than in the end. According to the neurotrophic factor hypothesis, post-
synaptic cells produce neurotrophic factors, which are needed for neuron survival, in li-
miting quantity. The consequence is that only neurons that synapse correctly (and con-
sequently have access to more quantities of neurotrophic factor) will survive, while the 
others will die for programmed cell death.56  Each sub-population of neurons depends on 
the actions of different neurotrophic factors.57 
 The first factor that was described as important for growth and survival of neu-
rons was the nerve growth factor.58 Today, we know four families of neurotrophic fac-
tors: neurotrophins, neurokines, glial cell line-derived neurotrophic factors (GFLs) and 
mesencephalic astrocyte-derived neurotrophic factor family (MANF). 
 
Neurotrophins 
 Neurotrophins belong to a superfamily of growth factors with a cysteine knot: this 
knot consists of three disulfide bonds formed by cysteine residues. Neurotrophins act as 
head-to-head dimers. To this cysteine knot-family belong also neurotrophic factors such 
                                                 
54 Por SB. & Huttner WB., A Mr 70000 phosphoprotein of sympathetic neurons regulated by nerve growth 
factor and by depolarization, J Biol Chem. (1984) 259:6526-33 
55 Barde YA., What, if anything, is a neurotrophic factor?, Trends Neurosci. (1988) 11:343-6 
56 Thoenen H.& Barde YA.,  Physiology of nerve growth factor, Physiol Rev. (1980) 60:1284-335 
57 Davies AM., The neurotrophic hypothesis: where does it stand?, Philos Trans R Soc Lond B Biol Sci. 
(1996)351:389-94 
58 Levi-Montalcini R. & Hamburger V, Selective growth factor stimulating effects of mouse sarcoma on 
the sensory and sympathetic nervous system of the chick embryo, J Exp Zool. (1951) 116:321-61 
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as GDNF and its family, TGFβ and PDGFs, and their three-dimensional structure is very 
similar despite the differences in the amino acidic sequences.59 
 Some neurotrophins are NGF, BDNF, NT-3 and NT-4/5, and their signalling is critical 
for maintenance and plasticity of the CNS, but they have a role also outside the nervous 
system, for example in the development of the heart.60 
 They are synthesized as large precursors that are processed to generate the pro-
forms, which sometimes have their own activity. For example proBDNF activates a re-
ceptor complex of p75 and sortilin and induces neuronal apoptosis.61 The pro-forms are 
eventually processed and generate the mature neurotrophins.62 
 The actions of these molecules are mediated by Trk receptors that have high af-
finity and are highly specific for the various neurotrophins and by p75 receptor that has 
a lower affinity.63 Trks are transmembrane receptors with an intracellular domain that 
has a tyrosine kinase activity: when the ligand is bound the tyrosines of this domain be-
come phosphorylated and this lead to the phosphorylation of other tyrosine residues that 
bind and activate various cytoplasmic proteins.64 There are also inactive variants of Trk 
receptors, whose function is still unknown, even if it is thought that they can have a 
dominant negative action.65 
The extracellular domain is composed by a cysteine-rich cluster, three leucine-rich re-
peats, another cysteine-rich cluster and two immunoglobulin-like domains that deter-
mine the affinity and specificity of the binding of the various ligands.66 
 The p75 receptor instead has a lower affinity for the mature forms of the neuro-
trophins, but is preferentially activated by pro-neurotrophins.67 One of its established 
functions is to promote cell death; however TrkA-induced survival signalling protects 
                                                 
59 Butte MJ, Neurotrophic factor structure reveals clues to evolution, binding, specificity, and receptor 
activation, Cell Mol Life Sci. (2001) 58:1000-13 
60 Tessarollo L. et al., Targeted deletion of all isoforms of the trkC gene suggest the use of alternate re-
ceptors by its ligand neurotrophin-3 in neuronal development and implicates trkC in normal cardiogene-
sis, Procl Natl Acad Sci USA (1997) 94:14776-81 
61 Teng HK. et al., ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR 
and sortilin, J Neurosci. (2005) 25:5455-63 
62 Butte MJ, Neurotrophic factor structure reveals clues to evolution, binding, specificity, and receptor 
activation, Cell Mol Life Sci. (2001) 58:1000-13 
63 Chao MV. & Hempstead BL., p75 and Trk: a two-receptor system, Trends Neurosci. (1995) 18:321-6 
64 Reichardt LF., Neurotrophin-regulated signalling pathways, Philos Trans R Soc Lon B Biol Sci (2006) 
361:1545-64 
65 Eide FF. et al., Naturally occurring truncated trkB receptors have dominant inhibitory effects on brain-
derived neurotrophic factors signalling, J Neurosci, (1996) 16:3123-9 
66 Urfer R. et al., An immunoglobulin-like domain determines the specificity of neurotrophin receptors, 
EMBO J. (1995) 14:2795-805 
Ultsch MH. et al., Crystal structures of the neurotrophin-binding domain of TrkA, TrkB and TrkC, J Mol 
Biol. (1999) 290:149-59 
67 Lee R. et al., Regulation of cell survival by secreted proneurotrophins, Science (2001) 294(5548):1945-
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neurons from p75-induced death pathway.68 
 
Neurokines 
 Neurokines are small molecules similar to cytokines that signal using common cy-
tokine receptor components. They consist of four helices forming a bundle and act pri-
mary as monomers, but dimer formation can occur at high protein concentrations.69 
 Their best characterized factor is CNTF that was shown to support survival of pa-
rasympathetic neurons form the chick ciliary ganglia and also to have trophic and diffe-
rentiating effects on different types of neurons and glia.70 Other factors from the same 
family include for example IL-6 and LIF, which have effects similar to the ones of CNTF 
on neurons, but have also an action on the rest of the body.71 
 Cytokines bind to a non-signalling α-receptor that is specific for each factor, and 
this induces the recruitment of two signalling receptors that can be homodimers of 
gp130 (for example for IL-6) or heterodimers (for example gp130 and LIFR for LIF; how-
ever it must be said that LIF does not need an α-receptor and binds directly to the hete-
rodimer). The intracellular domains of the dimers associate then with signalling mole-
cules such as Janus kinase, activating them.72 
 
MANF family 
 MANF and CDNF (Conserved Dopamine Neurotrophic Factor) have been crystallized 
very recently and they don't resemble any other known neurotrophic factor. They are se-
creted proteins with eight conserved cysteine residues and their N-terminus is a saposin-
like lipid binding domain, while the C-terminus contains a CKGC disulphide bridge.73 
 They are expressed in both CNS and non-neuronal tissues and it is known that they 
                                                 
68 Majdan M., et al., TrkA mediates developmental sympathetic neuron survival in vivo by silencing an 
ongoing p75NTR-mediated death signal, J Cell Biol. (2001) 155:1275-85 
69 Narhi LO. et al., Comparison of solution properties of human and rat ciliary neurotrophic factor, J 
Pept Res. (1997) 50:300-9 
70 Adler R. et al., cholinergic neuronotrophic factors: intraocular distribution of trophic activity for ci-
liary neurons, Science (1979) 204:1434-6 
Vergara C. & Ramirez B., CNTF, a pleiotropic cytokine: emphasis on its myotrophic role, Brain Res Brain 
Res Rev. (2004) 47:161-73 
71 Ip NY. & Yancopoulos GD., The neurotrophins and CNTF: two families of collaborative neurotrophic 
factors, Annu Rev Neurosci. (1996) 19:491-515 
72 Heinrich PC. et al., Principles of interleukin (IL)-6-type cytokine signalling and its regulation, Biochem 
J. (2003) 374:1-20 
Vergara C. & Ramirez B., CNTF, a pleiotropic cytokine: emphasis on its myotrophic role, Brain Res Brain 
Res Rev. (2004) 47:161-73 
73 Parkash V. et al., The structure of the conserved neurotrophic factors MANF and CDNF explains why 
they are bifunctional, Protein Eng Des Sel. (2009) 22:233-41 
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promote dopaminergic neurons survival.74 It has been proposed that they may have a 
role in inhibit ER stress-induced cell death.75 
 MANF and CDNF have a homologue in Drosophila melanogaster that is involved in 
development of DA neurons, however their receptors have not been found yet.76 
 
GFLs  
The first described member of this family was GDNF that was shown to promote 
survival in embryonic midbrain culture of dopaminergic neurons, where it actually regu-
lates TH expression and dopamine uptake.77 Other members of the same family are 
neurturin (NRTN), artemin (ARTN) and persephin (PSPN). 
 These molecules, together with neurotrophins, belong to the “cysteine knot” su-
perfamily. They have two cysteines connected by a polypeptide chain that form a cova-
lent ring through which passes a third cysteine, forming the knot that confers structural 
stability. GFLs act as homodimers, and each monomer has seven conserved cysteine resi-
dues: six of these form the knot, while the seventh forms an intermonomer cysteine 
bridge. 78 
 Only the structures of GDNF and artemin have been solved: they have an α-helix 
called “heel”, surrounded by flexible and less ordered stretches, and some β-sheets that 
form two fingers departing from the heel: finger 1 and finger 2. Finger 1 is more N-
terminal and is composed by two anti-parallel β-sheets separated by a turn of 310-helix, 
while finger 2 is more C-terminal and is made up of four β-sheets interrupted by short 
stretches. Two monomers form a head-to-tail dimer with the heel of one monomer close 
to the finger of the other (see Figure 11), and one of the differences between GDNF and 
ARTN is that GDNF is more flexible and bent than ARTN. In addition, ARTN has more 
curved fingers and this increases the buried surface area in the interface between mo-
nomers. It has been proposed that NRTN could be more “artemin-like”, while PSNP could 
                                                 
74 Petrova P. et al., MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity 
for dopaminergic neurons, J Mol Neurosci. (2003) 20:173-88 
Lindholm P. et al., Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in 
vivo, Nature (2007) 448:73-7 
Lindholm P. et al., MANF is widely expressed in mammalian tissues and differently regulated after 
ischemic and epileptic insults in rodent brain, Mol Cell Neurosci. (2008) 39:356-71 
75 Parkash V. et al., The structure of the conserved neurotrophic factors MANF and CDNF explains why 
they are bifunctional, Protein Eng Des Sel. (2009) 22:233-41 
76 Palgi M. et al., Evidence that DmMANF is an invertebrate neurotrophic factor supporting dopaminergic 
neurons, Proc Natl Acad Sci USA (2009) 106:2429-34 
77 Lin LF. et al., GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons, 
Science (1993) 260:1130-1132 
78 Parkash V. & Goldman A., Comparison of GFL-GFRalpha complexes: further evidence relating GFL bend 
angle to RET signalling, Acta Crystallogr Sect F Struct Biol Cryst Commun. (2009) 65(Pt 6):551-8 
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have a different conformation, and these differences could be related to RET signal-
ling.79  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 GFLs signal through a tetrameric receptor composed by two GFRα molecules and 
two RET receptor tyrosine kinases. GFLs cannot bind directly to RET, so they first bind to 
GFRα. These receptors are GPI-anchored molecules and can't mediate the signal through 
the membrane, but RET can bind to the GFL-GFRα complex, so that the signal is trans-
ferred to RET which transfers it inside the cell.80 There are four types of GFRα, and each 
is specific for a different GFL (see Figure 12): GDNF signals through GFRα1, neurturin 
through GFRα2, artemin through GFRα3 and persephin through GFRα4 (even if actually 
GDNF can bind also GFRα2 and GFRα1 can bind neurturin and artemin, too).81 
                                                 
79 Parkash V. & Goldman A., Comparison of GFL-GFRalpha complexes: further evidence relating GFL bend 
angle to RET signalling, Acta Crystallogr Sect F Struct Biol Cryst Commun. (2009) 65(Pt 6):551-8 
80 Durbec P. et al., GDNF signalling through the Ret receptor tyrosine kinase, Nature (1996) 381:789-93 
81 Trupp M. et al., Multiple GPI-anchored receptors control GDNF-dependent and independent activation 
of the c-Ret receptor tyrosine kinase, Mol Cell Neurosci. (1998) 11:47-63 
Figure 11. GDNF monomer has been crystallized from residue 34 to 134; in the picture the GDNF dimer is visible 
(one monomer is pink, the other light blue). In the figure the fingers (that are supposed to be important for GFRa1 
binding) and the N-terminus are marked. Finger 1 is composed by two β-strands, with the first one followed by a 
310-helix, while finger 2 is made up of four β-strands; the two fingers are connected by a region called “wrist” or 
“heel” represented by the α-helix. In the picture also the disulphide bonds forming the cysteine knot are visible 
(purple and yellow). 
From Virtanen H., 2009 
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 RET 
Figure 12. GFL and their GFRα receptors. 
Continuous arrows indicate the receptors for which the ligands have the highest affinity, while dashed arrows indi-
cate receptors that can bind the ligand but with a lower affinity. The importance of these interactions in vivo is still 
unknown 
It is possible to see the binding of an artemin dimer to the tetrameric receptor (composed by two GFRα3s and two 
RETs). This leads to the activation of RET and the intracellular signalling. 
GDNF can bind GFRα1 and GFRα2, like neurturin (but with different affinity), artemin can bind GFRα1 and GFRα3, 
while persephin can bind GFRα4 only. 
Abbreviations: ARTN = artemin, GDNF = glial cell line-derived neurotrophic factor, GPI = glycolphospatidylinositol, 
NRTN = neurturin, PSPN = persephin, RET = rearranged during transfection, TM = transmembrane domain. 
Modified from Bespalov MM. and Saarma M., 2007 
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In various cell types GFRαs are present at high levels, while RET is undetectable.82 
This could be explained by GFRα binding to other receptors than RET, or by formation of 
GFRα-RET complex produced by adjacent cells, or that RET is expressed by GFL-
responsive cell when GFRα is in soluble form. For example NCAM can function as a sig-
nalling receptor for GFLs, and it is thought that GFRαs can have also other functions, 
such as cell adhesion.83 
 All GFLs promote survival of dopaminergic neurons, so that has been proposed 
that they can have therapeutic potential in treatment of PD, but they have also other 
functions.84 
 
Artemin 
Artemin for example is a survival factor for sympathetic neurons and regulates 
sensory neurons, so that it has been considered for treatment of chronic pain.85 It is first 
produced as a pre-pro-protein, which is then cleaved; its mature form is more similar to 
neurturin and persephin than to GDNF, and it can strongly bind heparin.86 
 
Persephin 
Persephin has a 40% homology with GDNF and neurturin. It too has a pre-pro-form 
that is cleaved and produces a mature form of 96 amino acids that, differently from the 
other factors of this family, is not able to bind to heparin.87 Persephin promotes ureteric 
bud branching in vivo and basal forebrain cholinergic neurons in vivo.88 
 
                                                 
82 Trupp M. et al., Complementary and overlapping expression of glial cell line-derived neurotrophic fac-
tor (GDNF), c-RET proto-oncogene, and GDNF receptor-alpha indicates multiple mechanisms of trophic 
actions in the adult rat CNS, J Neurosci. (1997) 17:3554-67 
83 Paratcha G. et al., The neural cell adhesion molecule NCAM is an alternative signalling receptor for 
GDNF family ligands, Cell (2003) 113:867-79 
Ledda F. et al., GDNF and GFRalpha1 promote formation of neural synapses by ligand-induced cell ad-
hesion, Nat Neurosci (2007) 10:293-300 
84 Åkerud P. et al., Persephin-overexpressing neural stem cells regulate the function of nigral dopami-
nergic neurons and prevent their degeneration in a model of Parkinson's disease, Mol. Cell. Neurosci. 
(2002) 51:205-222 
85 Wang S. Elitt et al., Effects of the neurotrophic factor artemin on sensory afferent development and 
sensitivity, Sheng Li Xue Bao (2008) 60:565-570 
86 Alfano I. et al., The major determinant of the heparin binding of glial cell-line-derived neurotrophinc 
factor is near the N-terminus and is dispensable for receptor binding, Biochem J. (2007) 404:131-40 
87 Milbrandt J. et al., Persephin, a novel neurotrophic factor related to GDNF and neurturin, Neuron 
(1998) 20:245-53 
88 Åkerud P. et al., Persephin-overexpressing neural stem cells regulate the function of nigral dopami-
nergic neurons and prevent their degeneration in a model of Parkinson's disease, Mol. Cell. Neurosci. 
(2002) 51:205-222 
Golden JP. et al., Neurturin and persephin promote the survival of embryonic basal forebrain choli-
nergic neurons in vitro, Exp. Neurol. (2003) 184:447-455 
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Neurturin 
Neurturin has a pre-pro-form made up of 195 amino acids that is cleaved and ge-
nerates eventually the mature form, which is composed by 100 amino acids with a mole-
cular mass of about 12 KDa and has a 42% similarity with mature GDNF.89 Mature neurtu-
rin can bind heparin with a high affinity.90 Beside the survival and proliferation of dopa-
minergic neurons, it regulates the development of most parasympathetic neurons and in 
fact it was first isolated for this property.91 Neurturin can also induce branch initiation in 
kidney development.92 
 
GDNF 
About ten years ago many articles have been published about GDNF gene se-
quence and its promoter. This gene maps on chromosome 5 (5p12-p13.1) and is organ-
ized within 28 Kb, with a mature RNA of ~4.6 Kb. The translational start codon is local-
ized in exon 2 and it is thought that untranslated exon 1 can be involved in regulation of 
GDNF, as previously described for PLCγ2 and c-myc.93  
In mouse GDNF sequence there is an additional ATG within the open reading frame 
in exon 1, but this is not present in human GDNF and it is not in accordance with the 
consensus sequence for start codons, so probably it is not a real start codon. However, 
there is a TATA-box near exon 1 that is probably active: the 115 bp around this sequence 
share 95% identity between mouse and human, and in mouse transcription starts from 
that site.94 GDNF promoter is also rich in potential binding sites for repressive transcrip-
tion factors, such as epidermal growth factor receptor transcription factor (ETF), GC 
factor, and yin yang-1 that has been shown to be both an activator and repressor of tran-
scription, depending on the context.95 
A second putative promoter was detected in the first intron region (see Figure 
13): this is rich in CG (more than 72%) and lacks CCAT- and TATA-box, but contains how-
                                                 
89 Kotzbauer PT. et al., Neurturin, a relative of glial-cell-line-derived neurotrophic factor, Nature (1996) 
384:467-70 
90 Alfano I. et al., The major determinant of the heparin binding of glial cell-line-derived neurotrophinc 
factor is near the N-terminus and is dispensable for receptor binding, Biochem J. (2007) 404:131-40 
91 Rossi J. et al., Retarded growth and deficits in the enteric and parasympathetic nervous system in 
mice lacking GFRα2, a functional neurturin receptor, Neuron (1999), 212:243-252 
92 Davies JA et al., Neurturin: an autocrine regulator of renal collecting duct development, Dev. Genet. 
(1999) 24:284-292 
93 Grimm L. et al., Analysis of the human GDNF gene reveals an inducible promoter, three exons, a 
triplet repeat within the 3'-UTR and alternative splice products, Hum Mol Genet. (1998) 7(12):1873-86 
94 Ibid. 
95 Baecker PA. et al., Characterization of a promoter for the human glial cell line-derived neurotrophic 
factor gene, Molecular Brain Research (1999) 69:209–222 
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Figure 13. Sequence of GDNF promoter located 
within intron 1, showing where all the elements are 
located. Half sites of GDNF Promoter Repeat are 
indicated with arrows, and a putative site of initia-
tion of transcription is marked with +1. 
Abbreviations: CRE = cAMP response element, MRE = 
metal response element, MNF = myocite nuclear 
factor, bHLH = basic helix-loop-helix 
From Woodbury D. et al., 1998 
ever canonical cis-elements. For example, at least four Sp1 binding sites can be found: 
in genes that lack TATA-box, Sp1 protein is thought to anchor the transcriptional machin-
ery to the DNA, and since it is ubiquitous, a basal level of transcriptional competence is 
maintained in all the cells. It contains also a consensus sequence for a muscle-specific 
transcription factor (MNF), and this is in accordance with the fact that GDNF is detect-
able in mice at E15, the time of motoneuron innervation, and that spinal motoneurons 
can retrogradely transport GDNF that could act as a target-derived neurotrophic factor. 
It contains also many other cis-regulatory elements. For example there is an E-box that 
is recognized by bHLH factors that are required for development (particularly for myo-
genesis and neurogenesis). There are also three metal response elements that upregu-
late gene transcription in response to oxidative stress and the presence of high concen-
trations of such metals as cadmium, zinc and copper: it has been hypothesized that cel-
lular damage caused by ischaemia or trauma may increase levels of GDNF through these 
elements, and this may then limit further damage. Between the two 5’-most metal re-
sponse elements there are an NFkB site and a cAMP response-element, that may connect 
GDNF expression respectively to PCK and PKA pathways. There is also a Zif/268 site, and 
it is known that the mRNA for this transcription factor is upregulated by many events, 
included cell depolarization. Moreover, a novel putative cis-element was identified and 
named GDNF Promoter Repeat: this is composed by an inverted repeat with a half site of 
12 bp. The distance between the two mirror sites is 10 bp, which is exactly one turn of 
the DNA helix, and this places these half sites on the same side of the helix and makes 
interaction between proteins occupying easier. The half sequences are 100% conserved 
between rodents and humans, while the spacing sequence has only 30% conservation.96 
 
                                                 
96 Woodbury D. et al., Novel structure of the human GDNF gene, Brain Res. (1998) 803(1-2):95-104 
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 The polyadenilation signal is located 2.9 Kb distal of the stop codon. Comparison 
of human and mouse sequence shows a 87% homology for the most 5’ region of this se-
quence, 42% homology between the central region and 67% for the most 3’ sequence. In 
human this region contains ACG repeats, but it has been shown that they are not in-
volved in neurodegenerative diseases related to GDNF.97 
GDNF has different splice variants (see Figure 14). For example transcripts lacking 
the entire exon 2 and thus the corresponding start codon have been identified; there are 
two other in-frame ATGs downstream of the 5’ end of exon 3 and one of these is ho-
mologous to the Kozak leader sequence motifs. Products starting from here lack the 
preprosequence codified by exon 2 and could be retained within the cell, as it happens 
for other growth factors and cytokines. Another variant lacks 78 bp at the end of exon 2 
and has a divergent preprosequence that might be differently processed and/or se-
creted.98 
 
GDNF is expressed as a pre-pro-protein. The pre-sequence contains the signal 
peptide, which is cleaved upon secretion. The pro-form is then cleaved and the mature 
GDNF contains 134 residues. 
It was first known for its ability of promoting survival of embryonic dopaminergic 
midbrain neurons, but it is also useful for motor neurons and many other neuronal types 
in CSN and PNS.99 For example in the PNS it is important for differentiation of sympa-
                                                 
97 Grimm L. et al., Analysis of the human GDNF gene reveals an inducible promoter, three exons, a trip-
let repeat within the 3'-UTR and alternative splice products, Hum Mol Genet. (1998) 7(12):1873-86 
98 Ibid. 
99 Lin L-F. et al., GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons, 
Science. (1993) 260:1130-1132 
Henderson CE. et al., GDNF: a potent survival factor for motoneurons present in peripheral nerve and 
muscle, Science. (1994) 266:1062-1064 
Figure 14. Alternative splice 
variants of human GDNF 
gene. On the right cell lines 
where the cDNA was found 
are shown. The third variant 
that lacks completely exon 2 
has been identified only in 
one cell line, so it could be 
specific for that tumour cell 
line or developmentally spe-
cific. Also RT-PCR products 
are shown. 
Grey boxes indicate the 
preprosequence, while black 
boxes indicate the sequence 
codifying for the mature 
GDNF protein. 
From  Grimm L. et al., 1998 
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thetic, parasympathetic, sensory and enteric neurons.100 Moreover, knockout mice that 
lack GDNF show renal agenesis at birth, so this factor is important not only for the nerv-
ous system, but also for kidney morphogenesis.101 Other studies have shown also its im-
portance in spermatogonial development.102 During brain development, GDNF is pro-
duced in the olfactory bulb and promotes migration of neuronal precursors form the ro-
stral migratory stream to the olfactory bulb.103 GDNF is responsible also for the tangen-
tial migration of the precursors of GABAergic interneurons from the lateral ganglionic 
eminence to olfactory bulb, hippocampus and cerebral cortex.104 
GDNF can bind strongly to heparin; in fact when it was first purified in 1993 a he-
parin column was used. GDNF can bind also heparan sulphate that is localized on the cell 
surface and in the extracellular matrix and is structurally related to heparin: HS is syn-
thesized as a proteoglycan with a protein core and multiple glycosaminoglycan chains 
that are then modified. One of the modifying enzymes is HS 2-O-sulphotransferase and 
its KO in mice causes various defects, such as absence of kidneys that is very similar to 
what happens when GDNF, GFRα1 or RET are KO’d.105 The region of GDNF that is thought 
to be involved in heparan sulphate and heparin binding is just N-terminal to the cysteine 
knot and it is composed by basic amino acid-rich sequence of 16 residues: in 2007 Alfano 
et al., showed that if this region is deleted, GDNF is not binding to heparin. Moreover, in 
the post-helix region, another putative heparin binding sequence is present.106 
However, the role of heparin in GDNF signalling remains unclear: at low concentrations 
heparin protects GDNF from proteases and exogenous heparin has been shown to pro-
mote activity of GDNF in the induction of TH gene in neuroblastoma cells.107 Neverthe-
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less exogenous heparin can block GDNF activity in kidney cell line, probably because it 
sequesters GDNF. One of the hypotheses is that GAGs can bind GDNF and thus increase 
its local concentration on the membrane. Experiments have shown that GDNF binds spe-
cifically to heparan sulphate, while dermatan sulphate and chondroitin sulphate are less 
effective; it has been speculated also that GDNF might require specific types of heparan 
sulphates, and if it is true then GDNF signalling in vivo could be regulated at different 
levels. For example tissues in which GDNF is active during development, such as brain 
and kidneys, are rich in syndecans and glypicans and the specific composition of the HS 
chains carried by this molecules changes with time (both in length and 6-O-sulphation), 
and these changes could then have an effect on cells’ sensitivity to GDNF.108  
Mutagenesis of GDNF has shown where the important regions for binding of GFRα1 
are. Replacing short segments of finger 2 of GDNF with the homologous from persephin 
(that is not able to bind GFRα1) it is possible to see that GDNF does not activate GFRα1, 
while introduction of these regions into persephin shows that they are sufficient for ac-
tivation of GFRα1 (but not for GFRα2 that requires additional determinants, like seg-
ments from the heel). In GDNF dimer, finger 2 from one monomer and heel from the 
other form a continuous surface along the side and the bottom of the molecule, so this 
surface could be directly involved in GFRα binding. GFRα1 can be activated by GDNF, ar-
temin and neurturin and this is consistent with the fact that it has the most minimal re-
quirements for activation (just segments from the finger). The activation of GFRα2 and 
GFRα3 instead requires also segments from the heel, and moreover persephin mutants 
containing all these segments are not fully active, suggesting either that other segments 
are needed or that the binding determinants are not presented properly in the PSPN mo-
lecule.109 Other residues involved in GFRα binding were identified by Eketjäll et al.: four 
negatively charged residues (D52, E61, E62, D116) and four hydrophobic residues (I64, 
L114, Y120, I122) are crucial for receptor binding, while mutations of other residues 
(E58, K60, L118) caused smaller effects.110 
This study also show that the N-terminus of GDNF is important for receptor bind-
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ing, as its deletion affects GDNF activity, but a later study (Baloh RH. et al., 2000) had 
opposite results, so the role of N-terminus in receptor binding is still unclear. 
 
GFRαs 
 The first discovered GFRα was GFRα1 in 1996. Experiments showed that RET could 
be activated either by adding GDNF to cells expressing GFRα1 or by exposing cells that 
do not express it to GDNF and soluble GFRα1.111 
 GFRαs are as important as GFL for signalling; in fact mice lacking GFRα1 have def-
icits very similar to the ones of GDNF-deficient mice. They show, for example, deficits in 
kidneys, enteric nervous system, and in subpopulations of spinal motor neurons and sen-
sory neurons. In these mice dopaminergic neurons do not respond to GDNF, but can be 
rescued if exposed to GDNF in the presence of a soluble form of GFRα1, while subman-
dibular parasympathetic neurons just show normal response, so probably GDNF acts on 
these cells through a different receptor.112 
 GFRα receptors are GPI-anchored protein, thus they don't have a cytoplasmic do-
main that can mediate transmembrane signalling and need the presence of RET to trans-
fer the signal into the cell. Their length is generally about 400 amino acids, for example 
GFRα1 is synthesized as a 468 amino acid protein from which secretory and GPI-
anchoring signals are removed. They have three putative N-glycosylation sites and their 
molecular weight is around 47 KDa in the absence of glycosylation.113 
GPI-anchor can be cleaved, so that a soluble form of the receptor is generated. For ex-
ample in vivo GFRα1 is released by neurons of the enteric nervous system.114 It has also 
been proposed that alternative splicing could generate a soluble form of GFRα4, but so 
far there is evidence only at mRNA level.115 
 They are rich in cysteine with conserved spacing length between these cysteine-
rich domains, while the sequences of the joining segments are less conserved.  Generally 
(excluded GFRα4 that lacks domain 1, except in chicken) they have three of these do-
mains numbered starting from the N-terminus. Domain 1 is separated from domain 2 by 
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a long and flexible sequence, while domain 2 and 3 are quite near.116 
 The study conducted in 2001 by Scott and Ibañez concluded that domain 1 seemed 
to be dispensable for both ligand and RET binding, so they proposed that it could have 
function in subcellular sorting or in the interaction with other membrane molecules.117 
However a later study showed that full-length GFRα1 can bind GDNF more efficiently 
than truncated receptor. This property is detectable when the concentration of GFRαs is 
low, while at higher concentrations (either of the GPI-anchored protein or the soluble 
form) this effect is not visible, probably because at high GFRα concentration the amount 
of RET becomes rate limiting, so even if only a part of GFRαs are bound to GDNF this 
may still be enough to activate all available RET.118 
 Domain 3 is composed of five α-helices (α6-α10) with five disulphide bridges. The 
first two helices and the fourth form a central spiral, whose core contains hydrophobic 
residues. F263, F328 and F332 are highly conserved residues in the GFRαs.119 
 Domain 2 is homologous to domain 3 (whose structure has been used to model 
domain 2): it also contains five α-helices (α1-α5), but its structure is more compact. On 
its surface there are two largely positive charged areas, one defined by R224, R225, 
R217, H207 and K150, and the other, a potential heparin-binding site, composed by a 
BBBXBBXXB motif.120 
 Domain 2 and 3 are separated, but they form a globular structure, and the inter-
face between these two domains in hydrophobic with residues conserved in all GFRαs.121 
 The major determinant of ligand binding is in the central region of the receptor, 
which is also the most conserved, and is composed by four α-helices and two β-strands. 
The important motifs for GDNF binding are a hydrophobic triplet (MLF) in the first β-
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strand and a basic triplet (RRR).122 Another study pointed out the importance of other 
residues of the central region, such as N152, N153, R259, S316, N317 and S318 that were 
necessary for GDNF binding, while mutation of Q247, D248 and S249 caused reduced dif-
ferentiation and survival of PC12 cells to GDNF, suggesting that these residues may be 
not critical for ligand binding, but can have a modulatory function and influence the 
stability of the receptor complexes.123 Using previous information, crystal structure of 
domain 3 and predicted domain 2 structure, a model of the GDNF-GFRα1 was built. It 
was then used as a basis for site-directed mutagenesis, in order to discover which amino 
acid residues were implied in GDNF binding. Some of the residues involved in ligand 
binding or RET phosphorylation are F213, R224, R225 and I229, while the mutant R217E 
binds the ligand as strongly as the wild type receptor, but this strength remains the same 
in the presence and in the absence of RET, so it is thought that this arginine residue can 
have an allosteric function.124 In 2006 the structure of artemin bound to GFRα was 
solved: this molecule doesn't bind domain 3, but the tips of its fingers insert into the 
pocket created by the α-helices spiral. The residues involved are highly conserved and it 
is thought that they serve as common anchor points in all GFL-GFRα complexes and are 
surrounded by residues determining the specificity of binding between a GFL and its 
GFRα.125 
 Wang et al., while searching for residues involved in GDNF-GFRα interactions in 
2004, found out that mutation of residue R259 affected not only both GDNF and RET 
binding but also receptor complex activity; this residue is conserved in all GFRαs, and it 
is thought that it has the same function in all the receptors. Moreover, based on the 
study of conserved residues exposed on the surface of GFRαs, it has been proposed that 
the residues involved in RET binding are part of α2, α3, α7, α8, α9 and α10. This surface, 
in the artemin-GFRα3 complex is located next to the finger that could form part of a 
composite interaction surface. However this is still not confirmed experimentally.126  
 
RET 
 RET is a member of the receptor tyrosine kinase superfamily necessary for trans-
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duction of GFLs signalling when they bind to GFRαs. Thus RET is an important growth 
factor, but it can also be an oncogenetic protein (it can be found for example in human 
tumors of neural crest origin).127 Its dysfunction can lead to various inherited diseases, 
such as Hirschsprung's disease. 
It is possible that RET can function in the absence of GDNF as an apoptosis inducer and 
thus, in some conditions, it could be also a tumor suppressor.128 
 During development it is expressed in the developing excretory system, in PNS 
and in motor and catecholaminergic neurons in CNS, while during adult life RET is ex-
pressed in several neuron types and in chromaffin cells of the adrenal medulla.129 
 RET is synthesized as a non-phosphorylated monomer that needs to reach the cell 
surface to contact its ligands. It has 12 putative N-linked glycosylation sites, and it is 
first glycosylated in the endoplasmic reticulum, then it undergoes other modification in 
the Golgi apparatus, and its molecular weight increases from 120 KDa to 170 KDa. In 
many cell types RET is expressed as two forms: the 170 KDa is the mature glycosylated 
form and is localized on the cell surface, while another form of 150 KDa is sensitive to 
endoglycosidase-H. This means that is an immature form of RET, and experiments have 
shown that its localization is in the endoplasmic reticulum.130 
 Various isoforms of RET are generated by alternative splicing of its mRNA. The two 
best known isoforms share the first 1063 amino acids, but their C-termini are different: 
there are a short isoform (RET9) with a tail of 9 amino acids, and a long isoform (RET51) 
which has 51 amino acids in its C-terminus.131 The isoforms are differentially expressed, 
and in mouse tissues the short form of RET is predominantly expressed and it is impor-
tant for kidney and enteric nervous system development, while the long form is neces-
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sary for  metabolism and growth of mature sympathetic neurons and is probably more 
connected to tumor development.132  
 Mature RET is composed by four cadherin-like domains, a cysteine-rich domain, a 
transmembrane domain, a juxtamembrane domain, a kinase domain and a C-terminal 
tail.133 Cadherins need calcium for their function: Ca++ linearises the molecule and 
makes it more rigid, promote dimerization and protects cadherin from degradation. It is 
thought that calcium binding may play a similar role for RET, and indeed it has been 
shown that calcium binding site between cadherin-like domains 2 and 3 is important for 
correct folding of RET and its ligand-induced activation.134 Actually, single point muta-
tions in the calcium-binding cadherin-like domain or depletion of calcium abolish the 
expression of the mature form of RET on the cell surface. This is caused by an improper 
processing of RET in the endoplasmic reticulum.135 It has been proposed that the first 
three cadherin-like domains may have a role in ligand-binding, but later studies have 
shown that the fourth cadherin-like domain and the cysteine-rich domain, although not 
necessary for correct folding and maturation of RET extracellular domain, are needed 
for binding the GDNF-GFRα1 complex.136 The cysteine-rich domain is 117 amino acids 
long and contains 16 of the 28 cysteine of the extracellular domain. Of these 28 resi-
dues, 27 are conserved in human and mouse, so it is thought that they can be important 
for the formation of the tertiary structure of RET (for example by forming disulphide 
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bridges).137 
 The transmembrane domain of RET is important for non-covalent interactions be-
tween monomers so that the molecules can stay near and it is possible to form RET ho-
modimer.138 
 The juxtamembrane domain is between the transmembrane and the kinase do-
main. Tyr687 (which is phosphorylated in vitro) and Ser696 (that is a PKA binding site) 
are involved in the modulation of RET kinase activity by cAMP.139 Ser696 is needed for 
migration of enteric neural crest cells, and its mutation leads to absence of enteric 
nervous system in the distal colon.140 
 The kinase domain has a smaller N-lobe and a bigger C-lobe connected by a linker 
sequence and it occupies the most part of the intracellular portion of RET. This domain is 
followed by a tail that has different lengths depending on the isoform.141 
 When RET is activated, its Tyr1062 becomes phosphorylated. It has been proposed 
that the different activities of RET9 and RET51 may be the result of different regulation 
of this residue by the C-terminal sequence. Moreover, long isoform of RET has other two 
tyrosine residues that may undergo phosphorylation and participate in signalling events: 
Y1090 and Y1096. It has also been shown that the two isoforms interact differently with 
adapter proteins like SHC, GRB2 and Enigma, and that RET51 interacts more strongly 
than RET9 with Cbl ubiquitin ligase that leads to a faster turnover of long isoform of 
RET.142 
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GFL-GFRα-RET complex 
 As said earlier, GFL signalling is delivered into the cell through a complex com-
posed by the GFL dimer, two GFRαs and two RET molecules. The way this complex forms 
is still unclear: the first proposed model is that GFND binds to GFRα1, and this complex 
interacts with two RET molecules inducing homodimerization and tyrosine autophospho-
rylation. In this model GFL could either form together with GFRα a surface that binds 
RET or change the conformation of GFRα so that it can bind RET.143 However there is no 
clear evidence of this, and other models have been proposed. In the presence of GFRα, 
RET and GFL can be cross-linked, this means that they are at least quite close to each 
other.144 There are also evidences of a preassociation of GFRα and RET in absence of 
GFL.145 Moreover some GDNF mutants that can't bind GFRα1 can activate RET in the 
presence of GFRα1, so it can be proposed that there is a GFRα1-RET complex that has a 
higher affinity for GDNF than GFRα1 alone, or that RET stabilizes GDNF-GFRα com-
plex.146 (see Figure 15) 
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Figure 15. Complex formation. 
In model (a) GDNF dimer binds to 
a GFRα1 monomer, recruiting 
another GFRα1 receptor, this 
complex binds then two RET 
molecules. Alternatively GDNF 
dimer binds to a GFRα1 monomer 
and a RET molecule is recruited, 
a GFRα1 and a RET monomer are 
then bound.  
In model (b) complexes formed 
by GFRα1 and RET are already 
present, when GDNF is bound 
another GFRα1-RET heterodimer 
is recruited. 
In model (c) the heterotetramer 
composed by two molecules of 
RET and two of GFRα1 is present, 
and the binding of GDNF makes it 
change its conformation and 
become active. 
Abbreviations: CLD = cadherine-
like domain, CRD = cysteine-rich 
domain, D1, D2 and D3 = cys-
teine-rich domains of GFRα1 
From Bespalov MM. and Saarma 
M., 2007 
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 It has been proposed that GFRα domain 1 may be involved in the stabilization of 
the complex. This could be the consequence of a direct interaction between domain 1 
from one GFRα monomer forming the heterotetramer and domain 1 from the other, but 
in this case GFRα dimers should be detected even in the absence of GFL (unless the inte-
raction is very weak). Other possibilities are the direct interaction of domain 1 and 
GDNF, even if domain 1 is not the main responsible for GDNF binding, or interaction of 
domain 1 both with GDNF and a subdomain of GFRα1.147 
Tyrosine kinase receptors are activated when two monomers are brought together 
and can transphosphorylate each other. Actually, only some dimers are in an active con-
formation so that they can undergo transphosphorylation and stimulate downstream sig-
nalling proteins.148 Receptor monomers are in equilibrium with receptor dimers that can 
exist also in the absence of the ligand. When it binds to the receptor it can stabilize the 
dimer and stimulates downstream signalling. The same model, with the addition of 
GFRα, has been proposed also for RET signalling: monomers of RET and GFRα are in equi-
librium with active and inactive RET dimers and inactive GFRα-RET heterotetramers. 
This equilibrium can be pushed towards active dimers increasing the receptor density or 
by adding GFLs.149 
It has been proposed that this complex may be localized on lipid rafts rather than 
in the rest of the cell membrane. Lipid rafts are domains enriched with sphingolipids and 
cholesterol, that may have an important role in signal transduction, membrane traffick-
ing, cell adhesion and migrations, and many other function because they harbor specific 
proteins.150 For example, GPI-anchored proteins have been shown to localize on rafts, 
and, since many of them are co-receptors for transmembrane growth factor receptors, it 
is thought that GPI-anchored proteins can bring transmembrane receptor closer to sig-
nalling molecules also associated to lipid rafts, such as Src family kinases.151 GFRα1 has 
indeed been shown to recruit RET to lipid rafts after GDNF stimulation; in the experi-
ment a form of transmembrane GFRα1 that can't be recruited to rafts was used and the 
result was a decreased activation level of Src (and consequently of AKT and MAP kinases) 
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with a reduced neurite outgrowth and survival.152 However in a later study this result 
has been partly contradicted.153 
Other studies have also shown that when RET is localized on lipid rafts it is not 
degraded by the proteasome, so lipid rafts may be useful not only for RET signalling but 
also for protecting active dimers from degradation: it has been proposed that rafts may 
sequester active complexes from downregulation.154 
 
Signalling 
 All GFLs signalling through the GFL-GFRα-RET complex cause the phosphorylation 
of the intracellular tyrosine kinase domain of RET. Phosphorylated residues function then 
as docking sites for adapter proteins that activate various cellular signalling cascades 
regulating survival, differentiation, proliferation, migration, neurite outgrowth, synaptic 
plasticity and many other functions. 
 The intracellular domain of RET has various tyrosine residues that could be phos-
phorylated (see Figure 16). In vitro studies have identified some putative RET autophos-
phorylation sites (tyrosines 687, 806, 809, 826, 900, 905, 1015, 1029, 1062, 1090 and 
1096), but only five of these have been shown to become phosphorylated as a conse-
quence of ligand stimulation (residues 905, 981, 1015, 1062 and 1096).155 Of all these 
residues, Tyr1062 is the one that forms a docking site for the largest number of adaptor 
proteins. It can bind SHC, Enigma, FGF receptor substrate 2, Dok1/4/5/6, insulin recep-
tor substrate 1 and PKCα, and consequently is important for various functions related to 
neuronal survival and differentiation.156 Two protein complexes can then assemble on 
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SHC bound to Tyr1062: GRB2/Sos activates then RAS and ERK, while GRB2/GAB1 binds 
PI3K that can activate Rac (and then JNK) or AKT. Tyr1096 can bind GRB2/Sos directly, 
generating an alternative pathway for the activation of PI3K by GDNF.157 Tyr905 is a bind-
ing site for GRB7/10, while Tyr981 can bind Src and Tyr1015 is a docking site for PLCγ.158 
Studies on mutated forms of RET have shown that phosphorylation of other tyrosines 
(such as Tyr752 and Tyr928 that can bind STAT3) is implicated in multiple endocrine 
neoplasia 2A.159 Only quite recently information about normal functions of RET have 
been identified, since most of the information about the activated pathways were re-
lated to its oncogenetic role. When cells are exposed to GDNF, RET has been shown to 
increase tyrosine hydroxylase production both at mRNA and protein level, to induce the 
expression of a zinc finger protein (GZF1) that is important in renal branching morpho-
genesis, and to induce transcription of a transcriptional repressor (BMZF3).160 
 The elevation of cAMP levels has been found to cause Ser696 phosphorylation. 
This phosphorylation inhibits RET activity and, consequently, hinders lamellipodia forma-
tion in neuronal cells; it can also regulate JNK pathway and control the migration of en-
teric neural crest cell in the developing gut.161 
 This downstream signalling is negatively regulated by Sprouty2, a protein that re-
gulates signalling initiated by RTKs.162 RET can also interact with other proteins, such as 
protein phosphatases Shp-1 and Shp-2, LAR and PTPRJ. The latter two seem to reduce 
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Figure 16. Scheme of residues involved in RET activity. In red: mutation involved in RETMEN 2A phenotype. In blue: 
serine residue phosphorylated by PKA. 
Abbreviations: ERK = extracellular signal-regulated kinase, GAB = GRB2-associated binding protein, GRB = growth 
factor receptor-bound, IRS1 = insulin receptor substrate 1, JNK = c-Jun N-terminal kinase, PI3K = phosphoinositide 
3-kinase, PKCα = protein kinase C α, RAS = rat sarcoma oncogene, SOS = son of sevenless, 
the autophosphorylation of Tyr752 and 928 in RETMEN 2A mutants.163  
 
 
 
Each GFL has its own GFRα, so it is likely that each factor signals in a different 
way through RET. The signal could be different because of a different pattern of tyrosine 
phosphorylation or of a different duration of the phosphorylation. Actually, a study did 
not find significant differences in the phosphorylation of the key tyrosine residues, how-
ever further studies are required and differences in GFL signalling could be explained by 
their different expression pattern and by the existence of RET-independent signalling.164 
After ligand-induced activation of intracellular pathways, RET can be downregu-
lated. Usually RTK receptors are degraded in the lysosome, but RET degradation occurs 
in a proteasome-dependent way and polyubiquitination is made by two molecules: Cbl-3 
and CD2 associated protein.165 In some condition ubiquitinated RET co-localizes with 
early endosome markers after internalization. This is required not only for RET down-
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regulation but also for ERK1/2 complete activation.166 Also GFRα levels on the cellular 
surface lower after stimulation, this could be caused by GFRα internalization together 
with RET or by GFRα releasing from the cell surface by cleavage of their GPI-anchor.167 
The GDNF-RET signalling pathway has been shown to have cross-talks with other 
pathways, in different manners. For example EGFR can form a complex with RET and 
contribute to its activation, signalling, and growth stimulation.168 RET can also bind di-
rectly PKCα and activate it, as well as other protein kinases such as PKCδ and PKCζ. 
PKCα activation has a negative feedback on RET activity, since it promotes its phos-
phorylation on Ser/Thr and inhibits its activity.169 Cross-talk occurs also with NGF/TrkA: 
when NGF activates TrkA, RET phosphorylation increases in a GFL-independent way. This 
happens because NGF inhibits ubiquitin-dependent RET degradation, so that the amount 
of phosphorylated RET increases, and seems to be unidirectional, as GFLs do not have 
the same effect on TrkA activity. NGF-induced RET phosphorylation occurs more slowly 
than GFLs-induced ones, and another difference is that in the presence of NGF Tyr905 
and Tyr1062 are more autophosphorylated than in the presence of GDNF, so they may 
have different signalling capacities.170 Another cross-talk is the one between TGFβ and 
GDNF pathway: the neurotrophic effects of this ligand require the presence of TGFβ, 
both in vivo and in vitro. This factor is needed for recruitment of GFRα1 on the cellular 
surface.171 
 
Related diseases 
GDNF, GFRα1 and RET have a very important role during development. Mice lack-
ing one of these molecules show kidney agenesis and lack of enteric neurons and die 
shortly after birth.172 However, while up to 30% of GDNF +/- mice show renal abnormali-
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ties, GFRα1 +/- and RET +/- mice have normal kidneys.173  
GDNF is also needed for spermatogonial self-renewal and differentiation.174 On 
the contrary, mice with KO of other GFLs or other GFRαs are fertile and viable.175 
 
Hirschsprung’s disease 
Hirschsprung’s disease occurs in 1/5000 live births. It is a congenital disorder 
characterized by absence of enteric ganglia along part of the intestine that leads to in-
testinal obstruction or chronic constipation.176 There are different genes linked to this 
disease, included GDNF, NRTN and RET. 
Heterozygous mutations in RET gene are associated with Hirschsprung’s disease in 
50% of familial cases and in 15% of sporadic cases.177 These mutation can occur through-
out the RET gene and cause a reduction in the amount of RET protein or the loss of its 
function. For example, mutations in the kinase domain of RET can reduce its catalytic 
activity or affect binding of signalling molecules to RET.178  Mutations in the extracellular 
domain can instead interfere with RET maturation and its translocation to the cellular 
membrane.179 Moreover, mutations of the extracellular cysteines are also associated with 
other diseases such as MEN 2A, that in some cases can co-segregate with Hirschsprung’s 
disease. It is thought that this double effect may be caused by the dual effect of this 
mutation: it affects the extracellular domain, so maturation of RET does not occur cor-
rectly and RET level on the cell membrane is reduced (and this leads to death of enteric 
neurons), but it also can cause formation of intramolecular disulphide bridges that gen-
erate a constitutively active form of RET (that in some tissues can cause abnormal pro-
liferation and tumours).180 
Also GDNF mutations can be associated with Hirschsprung’s disease, however it 
seems that these mutations alone are not sufficient to lead to the disease, but other 
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mutations (for example on the RET gene) are needed.181 The same is for the neurturin 
mutation that alone does not cause Hirschsprung’s disease.182 
Mutations in GFRαs do not seem to be involved in Hirschsprung’s disease, even if 
abnormal expression of these receptors may be involved in its pathogenesis.183 
 
Medullary thyroid carcinoma and papillary thyroid carcinoma 
 RET is expressed in many tumours of neural crest origin. For example it is mu-
tated in medullary thyroid carcinoma, a tumour of the parafollicolar cells that produce 
calcitonin. There are three different hereditary cancer syndromes in which MTC can be 
found: multiple endocrine neoplasia type 2A and 2B (MEN 2A and MEN 2B) and familial 
medullary thyroid carcinoma (FMTC).184 The phenotype depends on the localization of 
the mutation, for example in MEN 2A mutations are usually in the cysteine-rich domain, 
while in MEN 2B are in the kinase domain and in FMTC can be in both these domains.185 It 
has also been suggested that mutation of GFRα4 can cause MEN also in the absence of 
mutations of RET.186 
 MEN 2A is the most common of these syndromes, and patients develop MTC, 
phaeochromocytoma (in about 50% of the cases) and hyperparathyroidism (in about 15-
50% of the cases).187 It is associated with mutation of one of the cysteines in the cyste-
ine-rich domain (usually Cys634, but also the other may be mutated): this leaves one of 
the cysteines in this domain without a pair, and it's thought that this cysteine may inte-
ract with the cysteine of another RET monomer and form a disulphide bridge that stabi-
lizes RET dimer.188 Folding of proteins takes place in the endoplasmic reticulum and it is 
                                                 
181 Salomon R. et al., Germline mutations of the RET ligand GDNF are not sufficient to cause Hirsch-
sprung disease, Nat Genet. (1996) 14(3):345-7. 
182 Doray B. et al., Mutation of the RET ligand, neurturin, supports multigenic inheritance in Hirsch-
sprung disease, Hum Mol Genet. (1998) 7(9):1449-52. 
183 Lui VC. et al., Glial cell line-derived neurotrophic factor family receptors are abnormally expressed 
in aganglionic bowel of a subpopulation of patients with Hirschsprung's disease, Lab Invest. (2002) 
82(6):703-12 
184 Skinner MA. et al., Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A, N Engl J Med. 
(2005) 353-1105-13 
185 Mulligan  LM. et al., Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report 
of the International RET Mutation Consortium, J Intern Med (1995) 238:343-6 
Eng  C. et al., Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple 
endocrine neoplasia type 2B and related sporadic tumours, Hum Mol Genet. (1996) 3:237-41 
186 Vanhorne JB. et al., A model for GFR alpha 4 function and a potential modifying role in multiple en-
docrine neoplasia 2, Oncogene (2005) 24:1091-7 
187 Hansford JR .& Mulligan LM., Multiple endocrine neoplasia type 2 and RET: from neoplasia to neuro-
genesis, J Med Genet. (2000) 37:817-27 
188 Mulligan LM. & Ponder BA., Genetic basis of endocrine disease: multiple endocrine neoplasia type 2, J 
Clin Endocrinol Metab. (1995) 80:1989-95 
Santoro M. et al., Activation of RET as a dominant transforming gene by germline mutations of MEN2A 
and MEN2B, Science (1995) 267:381-3 
 Introduction – GDNF, its receptor complex and signalling 
48 
 
thought that  active RET dimers can be already present before reaching the cell surface. 
 MEN 2B patients develop also MTC and phaeochromocitoma (50% of the cases), but 
hyperparathyroidism is less common. Moreover MEN 2B is characterized by marfanoid 
habitus, thickened corneal nerves and ganglioneuromatosis of buccal membranes and 
gastrointestinal tract.189 Mutations are localized in the substrate binding pocket of the 
kinase domain, and it is thought that they may result in an altered substrate specifici-
ty.190 
 FMTC is the less aggressive of these diseases, but sometimes is difficult to tell if a 
patient suffers from FMTC or MEN 2A, especially if the family is small and phaeochromo-
citoma and/or hyperparathyroidism have a late onset. This is also because mutations in-
volved in FMTC are the same that can be found in MEN 2A, a part from mutation of 
Cys634 that is not present in FMTC patients.191 
 Papillary thyroid carcinoma is also associated with RET mutations. In this case RET 
is activated in follicular cells (where normally is not expressed) by chromosomal rear-
rangement in which the kinase domain of RET is fused to a dimerizing domain encoding 
part of unrelated genes.192 The fusion RET/PTC protein tends then to dimerize sponta-
neously in the cytosol, and the kinase domain can bind adaptor proteins and activate 
signalling cascades.193 
 
Parkinson's disesase 
 We already discussed about PD earlier in the first part of the introduction, but 
how is it related to GDNF signalling? The locomotor symptoms of PD are caused by the 
degeneration of dopaminergic neurons in the SNc that project to the striatum. 
 Neurotrophic factors are really important for dopaminergic neurons, and for all 
kinds of neural cells in general. Usually it is difficult to study the effects of KO of even a 
single factor, because animals die shortly after birth: KO of GDNF, GFRα1 or RET does not 
seem to affect substantia nigra, since it does not show significant differences if com-
pared with that of wild type mice. GDNF-deficent mice show deficits in dorsal root gan-
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glion, sympathetic and nodose neurons, they completely lack enteric nervous system, 
kidneys and ureters, but not midbrain dopaminergic neurons or noradrenergic neurons 
from hindbrain.194 Mice that lack GFRα1 instead show renal agenesis and absence of en-
teric nervous system, but only minimal losses in some peripheral ganglia, as the nodose, 
were observed, so the authors suggest that there should be cross-talks between GDNF 
and other GFRαs at peripheral ganglia level. GFRα1-deficient mice also do not show 
losses of dopaminergic neurons in the midbrain, supporting the idea that GDNF signalling 
pathway is not involved in the development of dopaminergic neurons at pre-natal stag-
es.195 
However, this does not tell us if GDNF signalling pathway is involved in the maintenance 
of dopaminergic neurons, so in some studies ventral midbrain dopaminergic tissues from 
GDNF -/-, GDNF +/- and wild type mice have been transplanted to adult mice. Results 
have shown that development of DA neurons is reduced in GDNF -/- tissues, and that this 
can be rescued by immersion in GDNF before grafting. The authors then try to answer 
the question why the absence of GDNF in the early fetal development leads to post-natal 
loss of dopaminergic neurons in GDNF -/- mice. One possibility is that locally synthesized 
GDNF in wild type grafts enhances postnatal survival, while the absence of GDNF in the 
GDNF -/- transplants increases apoptosis; this can be rescued exposing tissues to GDNF, 
and the effects of this exposition can derive both from the high concentration of GDNF 
used (about 100-fold greater than the ED50 for GDNF-GFRα1 interactions) or from the 
fact that GDNF has a long half-life in the tissues of central nervous system (about 3-4 
days, and after intracerebroventricular injection GDNF is present for at least 7 days) and 
its effects last for at least three weeks in vivo.196 
In another study, to avoid the problem of postnatal survival, were used mice with selec-
tive ablation of RET. Absence of RET in the nervous system allows the establishment of 
the nigrostriatal system, but leads to progressive loss of dopaminergic neurons in the 
SNc, degeneration of their terminals in the striatum, reduced levels of evoked dopamine 
release and pronounced glial activation, showing that RET is important for the mainten-
ance of the nigrostriatal dopaminergic system. In aged mice, loss of the extent of target 
innervation was more pronounced than loss of dopaminergic cells, in accordance with 
observations made on PD patients and MPTP-models. Requirement for RET is region spe-
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cific, as losses in nigrostriatal pathway were more marked than in the mesolimbic path-
way (from VTA to the striatum), so the authors suggest that RET could be important but 
not essential for cells in the ventral tegmental area.197 On the other hand, other studies 
had opposite results and showed that RET is not necessary for maintenance of dopami-
nergic neurons since its deficiency does not cause major sensorimotor abnormalities.198 
However, in this study mice were followed for a shorter period than in the one described 
before, and this can be the reason for the different results. 
 In another study on mice with selective RET ablations has been demonstrated that 
in MPTP-models, RET facilitates the regeneration of dopaminergic axon terminals, but 
it's not effective against the loss of dopaminergic neurons caused by MPTP.199  
Studies on GDNF knock-out mice in which GDNF expression is suppressed during 
adulthood show that lack of GDNF leads to catecholaminergic cell death affecting locus 
coeruleus, substantia nigra pars compacta, and ventral tegmental area. These mice also 
show decrease of tyrosine hydroxylase mRNA in the brain and motor symptoms such as 
hypokinesia. The dependence of neuron survival on GDNF is observed also when GDNF is 
about 40% of its normal content in adult brain, and not only when GDNF is KO’d. In this 
study the authors also hypothesize that differences between their results and that of 
other studies in which GDNF seems to be unnecessary for maintenance of dopaminergic 
neurons could be explained by the fact that if GDNF is KO’d during the embrionic devel-
opment other alternative and compensatory pathways may become involved.200 These 
results are in agreement with the ones of another study in which the constitutive activa-
tion of RETMEN 2B was seen to increase the number of dopaminergic neurons in the stria-
tum, cortex and hypothalamus. Serotonin levels were not affected and those of nora-
drenaline were slightly higher only in the lower brain stem, while TH levels were in-
creased in the striatum (where the levels of DA transporter were also increased), in the 
substantia nigra pars compacta, and in the ventral tegmental area. This suggest that 
GDNF signalling via RET is important for maintenance of dopaminergic system. It has 
been shown that nigral dopaminergic neurons undergo apoptosis during the first three 
weeks after birth, and that survival of these cells is enhanced in mice over-expressing 
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GDNF in dopaminergic targets, so the increased number of TH-positive cells can derive 
from the fact that RET pathway is always active and rescues more neurons during these 
three weeks, or from the fact that this pathway leads more neurons to acquire a dopa-
minergic phenotype during postnatal development.201 
 However, it seems that genetic variations of RET in humans are not involved in re-
duced signalling in PD, as a relationship between RET polymorphisms and PD has not 
been found, and there are not reported cases of Hirschsprung's disease associated with 
PD. Anyway, the authors of this study suggest that GDNF signalling through RET could be 
disturbed at other levels in PD, for example expression or post-translational modifica-
tions of RET or even co-factors required for its signalling can be altered.202 
                                                 
201 Mijatovic J. et al., Constitutive Ret activity in knock-in multiple endocrine neoplasia type B mice in-
duces profund elevation of brain dopamine concentration via enhanced synthesis and increases the num-
ber of TH-positive cells in the substantia nigra, J Neurosci. (2007) 27:4799-809 
202 Lücking CB. et al., Polymorphisms in the receptor for GDNF (RET) are not associated with Parkinson's 
disease in Southern Germany, Neurobiol Aging. (2008) Apr. 22 [Epub ahead of print] 
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The initial characterization of GDNF showed that it is a heparin-binding, basic 
protein that is heterogeneously glycosylated and migrates on SDS-PAGE with a mass of 
about 33-45 kDa. The mass of the monomer becomes about 16 kDa after deglycosylation 
with N-Glycanase.203 Not much more is known about glycosylation and other modifica-
tions that can occur to GDNF or about is synthesis, transport and degradation. 
Human GDNF molecule is shown to have two predicted glycosylation sites. The 
first site is on the tip of the first finger, close to residues involved in GFRα1 binding, and 
could thus be involved in receptor specificity; the second site is instead predicted to be 
in the α-helix region, close to a predicted nardilysine cleavage site and to a furin cleav-
age site, so we thought that the glycosylation here could protect GDNF from cleavage, 
stabilizing the molecule (see Figure 17). 
  
 
 
 
 
 
 
 
 
  
 Since this molecule has a clinical relevance it is important to understand better 
the mechanism underlying its processing, so this study was aimed at understanding 
whether the putative N-glycosylation sites and the furin cleavage site are in use or not, 
and (in case they are) their roles. 
                                                 
203 Lin LF. et al., Purification and initial characterization of rat B49 glial cell line-derived neurotrophic 
factor, J Neurochem. (1994) 63(2):758-68 
Figure 17. Sequence of human GDNF.  
Prediction of signal peptide, prosequence and furin cleavage sites has been made with ProP, prediction of N-glycosylated 
sequences has been made with NetNGlyc, and all the other predictions have been made using ELM, on ExPASy website. 
AAA = signal peptide BBB = propeptide sequence CCC = α-helix DDD = β-strand EEE = 310-helix 
C = residue forming the cysteine-knot. Residues with the same symbol form a disulphide bridge. Cys178 forms a S-S link 
with the corresponding residue on the other monomer, stabilizing the dimer. 
FFF = residues involved in GFRα1 binding 
GGG = sequences predicted to be N-glycosylated 
red background = cleavage site 
A slash corresponds to a furin cleavage site, while superscript numbers indicate cleavage sites of other enzymes: 1 = nar-
dilysine 2 = NEC1/NEC2 3 = PC7  
a yellow background corresponds to a neutral prediction, a green background to a sparse/smart filtered motif. 
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Computational analysis 
 Computational analysis was performed using NCBI-BLAST2 (EBI website) in order 
to find GDNF sequences in all the species where this has been determined. The se-
quences were then aligned using Clustal W2 (EBI website). 
 Predictions of signal peptide and furin cleavage sites were made with ProP (Ex-
PASy website), while that of putative N-glycosylation sites was performed using Net-
NGlyc (ExPASy website) and every other prediction was made using ELM (ExPASy web-
site). 
 The cladogram of various GDNF sequences was drawn using Clustal W2 (EBI web-
site). 
 
Productions of GDNF variants 
Mutagenic PCR 
 Mutagenic PCR was performed in order to obtain GDNF variants with mutations on 
the predicted furin cleavage site and on the putative N-linked glycosylation sites. GDNF 
sequence is the one reported in Figure 18, while the plasmid used was the one from 
Figure 19. 
atgaagttatgggatgtcgtggctgtctgcctggtgctgctccacaccgcgtccgccttcccgctgcccgccggtaagaggcctcccgaggcgcccgcc 
 M  K  L  W  D  V  V  A  V  C  L  V  L  L  H  T  A  S  A  F  P  L  P  A  G  K  R  P  P  E  A  P  A   
Gaagaccgctccctcggccgccgccgcgcgcccttcgcgctgagcagtgactcaaatatgccagaggattatcctgatcagttcgatgatgtcatggat 
 E  D  R  S  L  G  R  R  R  A  P  F  A  L  S  S  D  S  N  M  P  E  D  Y  P  D  Q  F  D  D  V  M  D   
tttattcaagccaccattaaaagactgaaaagggactacaaggacgatgacgacaagggaggatcaccagataaacaaatggcagtgcttcctagaaga 
 F  I  Q  A  T  I  K  R  L  K  R  D  Y  K  D  D  D  D  K  G  G  S  P  D  K  Q  M  A  V  L  P  R  R 
gagcggaatcggcaggctgcagctgccaacccagagaattccagaggaaaaggtcggagaggccagaggggcaaaaaccggggttgtgtcttaactgca 
 E  R  N  R  Q  A  A  A  A  N  P  E  N  S  R  G  K  G  R  R  G  Q  R  G  K  N  R  G  C  V  L  T  A   
atacatttaaatgtcactgacttgggtctgggctatgaaaccaaggaggaactgatttttaggtactgcagcggctcttgcgatgcagctgagacaacg 
 I  H  L  N  V  T  D  L  G  L  G  Y  E  T  K  E  E  L  I  F  R  Y  C  S  G  S  C  D  A  A  E  T  T 
tacgacaaaatattgaaaaacttatccagaaatagaaggctggtgagtgacaaagtagggcaggcatgttgcagacccatcgcctttgatgatgacctg 
 Y  D  K  I  L  K  N  L  S  R  N  R  R  L  V  S  D  K  V  G  Q  A  C  C  R  P  I  A  F  D  D  D  L   
tcgtttttagatgataacctggtttaccatattctaagaaagcattccgctaaaaggtgtggatgtatctga 
 S  F  L  D  D  N  L  V  Y  H  I  L  R  K  H  S  A  K  R  C  G  C  I  - 
 
1. First N-glycosylation site mutant 
Primers used:  Forward: 5’-CTGTCACTGACTTGGGTCTGGGCT-3’  
 Reverse: 5’-CCGGGGTTGTGTCTTAACTGCAATACATTTAG-3’  
The sequence becomes then: 
tgtgtcttaactgcaatacatttagctgtcactgacttgggtctgggctatgaaaccaaggag 
 C  V  L  T  A  I  H  L  A  V  T  D  L  G  L  G  Y  E  T  K  E  
2. Second N-glycosylation site mutant 
Primers used: Forward:  5’-CCTTATCCAGAAATAGAAGGCTGGTGA-3’ 
 Reverse: 5’-TGAGACAACGTACGACAAAATATTGAAAG-3’ 
Figure 18. GDNF nucleotidic and amino acidic sequences. GDNF with a flag-tag (in red) linked to the experimentally 
determined N-terminus through a linker sequence (in green) was used. The underline marks the ER-signal sequence. 
Other colours indicate the first N-glycosylation site (blue), the second (yellow) and the furin cleavage site (purple). 
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The sequence becomes then: 
tacgacaaaatattgaaagccttatccagaaatagaaggctggtgatgagacaacg 
 Y  D  K  I  L  K  A  L  S  R  N  R  R  L  V  E  T  T 
3. Furin cleavage site mutant 
Primers used: Forward:  5’-CGCTGGTGAGTGACAAAGTAGGGCAG-3’ 
  Reverse: 5’-CAAAATATTGAAAAACTTATCCAGAAATAGAG-3’ 
The sequence becomes then: 
caaaatattgaaaaacttatccagaaatagagcgctggtgagtgacaaagtagggcag 
  K  I  L  K  N  L  S  R  N  R  A  L  V  S  D  K  V  G  Q   
4. Furin cleavage site and second N-glycosylation site mutant 
Primers used: Forward:  5’-GAAATAGAGCGCTGGTGAGTGACAAAGTAGGG-3’ 
  Reverse: 5’-ACAACGTACGACAAAATATTGAAAGCCTTATCCA-3’ 
The sequence becomes then: 
caaaatattgaaagccttatccagaaatagagcgctggtgagtgacaaagtagggcag 
  K  I  L  K  A  L  S  R  N  R  A  L  V  S  D  K  V  G  Q   
5. First and second N-glycosylation sites mutant 
Primers used for mutant 1 were used on the sequence of mutant 2 in order to obtain 
a new GDNF mutant with mutation of both N-glycosylation sites. 
The sequence became then: 
ttagctgtcactgacttgggtctgggcggtggtggtctgggctatgaaaccaaggaggaactgatttttaggtac 
 L  A  V  T  D  L  G  L  G  Y  E  G  L  G  Y  E  T  K  E  E  L  I  F  R  Y 
tgcagcggctcttgcgatgcagctgagacaacggcagctgagacaacgtacgacaaaatattgaaagccttatcc 
 C  S  G  S  C  D  A  A  E  T  T  A  A  E  T  T  Y  D  K  I  L  K  A  L  S   
 
6. First N-glycosylation site mutant without prosequence 
Primers used for mutant 1 were used on the sequence of a GDNF variant which has 
the ER-signal sequence directly linked to the flag-tag without the intermediate 
prosequence. 
The sequence became then: 
tgtgtcttaactgcaatacatttagctgtcactgacttgggtctgggctatgaaaccaaggag 
 C  V  L  T  A  I  H  L  A  V  T  D  L  G  L  G  Y  E  T  K  E  
as in mutant 1. 
 
The amplification protocol was as follows: 
1. 98 oC, 2 minutes: initial denaturation 
2. 98 oC, 20 seconds: denaturation 
3. 72 oC, 4 minutes: elongation 
4. Repeat from step 2, 24 times 
5. 72 oC, 10 minutes: final elongation 
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Figure 19. Scheme of the plasmid 
used, the sequence of the multiple 
cloning site is also shown. 
The size of the plasmid is 4.5 Kb, 
while the size of the insert is around 
0.7 Kb, thus the bands should have a 
size of approximately 5.2 Kb. 
 
CMV promoter: 9-667 
β-globin intron: 675-1167 
multiple cloning site: 1175-1250 
hGH polyA: 1246-1732 
pUC origin: 1893-2560 
resistance to ampicillin: 2708-3568 
f1 origin: 4807-4393 
 
Primers used for sequencing pair with 
β-globin intron and hGH poly A. 
6. 4 oC, 10 minutes: cooling down 
 
After running the analytical gel (agarose 1%) to make sure that the insert was pre-
sent, 45 µl of plasmid were treated with 2 µl of DpnI and incubated for 2.5 hours at 37 
oC in order to get rid of original unmutated DNA. These samples were then run on the 
preparative gel (agarose 0.8%), and the bands of the right size weight were cut and ex-
tracted from the gel using QIA quick gel extraction kit (QIAGEN) and eluted in 40 µl of 
MilliQ water. 
 
 
Plasmid phosphorylation and ligation 
5 µl of T4DNA ligase buffer (Fermentas), 2 µl of T4 polynucleotide kinase (Fer-
mentas) and 3 µl of MilliQ water were added to the eluted sample. After 1 hour incuba-
tion at 37 oC, the enzyme in the sample was inactivated by heating the mixture for 20 
minutes at 65 oC. Ligation was made soon after phosphorylation using 5 µl of phosphory-
lated PCR fragment, 4 µl of ligase buffer (Fermentas), 2 µl of T4DNA ligase (Fermentas) 
and 29 µl of MilliQ water. The mixture was incubated overnight at 14 oC. 
 
Transformation of E. coli cells 
The next day competent E. coli cells (strain DH5α) were transformed with the 
product of ligation: these cells were stored at -80 oC, and melted on ice before adding 5 
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µl of plasmid. After 30 minutes on ice the cells were subjected to heat-shock (90 sec-
onds at 42 oC and then returned on ice). 800 µl of SOC medium (2% w/v tryptone, 0.5% 
w/v yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2 or 20 mM MgSO4, 20 mM glu-
cose in ddH2O) were then added before incubating the cells for one hour at 37 
oC, shaking 
them at 220 rpm. They were then spun down by centrifuging at 17000 g, the supernatant 
was removed and 200 µl of fresh SOC medium were added. Cells were then plated on 
agar plates with ampicillin and incubated over night at 37 oC. 
 
Plasmid purification 
The next day single colonies were selected, transferred to glass tubes containing 
4 ml of LB medium and ampicillin 100 µM and incubated overnight at 37 oC and shaken at 
220 rpm. 
The plasmid was then purified using QIA Prep Spin Miniprep Kit (QIAGEN) and con-
centration of DNA was measured. In order to verify the presence of the insert, 1 µg of 
sample was digested with 0.5 µl of BamHI (Fermentas) and 0.5 µl of XhoI (Fermentas) in 
the presence of 2 µl of Tango buffer (Fermentas) in a total volume of 10 µl. After 1.5 
hours of incubation at 37 oC, the sample was run on an analytical gel (agarose 1%). 
 
Verifying the presence of the mutation 
DNA was sent to sequencing using primers pairing to β-globin intron and hGH polyA 
sequences of the pCMV-MCS plasmid. 
Sequencing results were then analyzed using Translate on ExPASy website and 
Align on EBI website. 
 
Cell culture 
CHO cells 
CHO cells were cultured in DMEM with 10% fetal bovine serum and 5% Pest. Cells 
were splitted 1:5 every second day. 
 
MG87-RET cells 
MG87-RET cells were cultured in DMEM with 10% fetal bovine serum, 5% Pest and 
puromycin 2 µg/ml. Cells were splitted 1:3 every second day. 
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Transfection 
Transfection of CHO cells, 60 mm plates 
CHO cells were obtained from a full 10 cm plate and plated on 60 mm plates with 
a dilution of 1:4. The next day 6.0 µg of DNA were added to 600 µl of DMEM and 12 µl of 
TurboFect (Fermentas) and after 20 minutes at room temperature 600 µl of the mixture 
were added to the cells in 5.4 ml of CHO medium. After 4 hours the medium was re-
placed with 4 ml of fresh CHO medium. 
 
Transfection of CHO cells, 24-well plate 
CHO cells were obtained from a full 10 cm plate and plated on 24-well plate with 
a dilution of 1:4. The next day 1.0 µg of DNA was added to 100 µl of DMEM and 2 µl of 
TurboFect (Fermentas) and after 20 minutes at room temperature 100 µl of the mixture 
were added to the cells in 900 µl of CHO medium. After 4 hours the medium was re-
placed with 400 µl of fresh CHO medium. 
 
Transfection of MG87-RET cells, 60 mm plates 
MG87-RET cells were obtained from a full 10 cm plate and plated on 60 mm plates 
with a dilution of 1:2. The next day 6.0 µg of DNA were added to 600 µl of DMEM and 12 
µl of TurboFect (Fermentas) and after 20 minutes at room temperature 600 µl of the 
mixture were added to the cells in 5.4 ml of MG87-RET medium. After 4 hours the me-
dium was replaced with 4 ml of fresh MG87-RET medium. 
 
Cotransfection 
Cotransfection was performed in the same way as transfection with TurboFect, 
but the total amount of DNA was doubled. Plasmids were transfected in a 1:1 ratio. 
 
Glycosylation of GDNF 
Treatment with PNGase F 
9 µl of medium collected from CHO cells transfected with plasmids encoding dif-
ferent GDNF variants were first denatured by heating at 100 oC for 10 minutes in the 
presence of 1 µl of Denaturing Buffer 10x (SDS 5%, DTT 0.4 M, from New England Bio-
labs). Then 2 µl of 10x G7 Reaction Buffer (sodium phosphate 0.5 M, from New England 
Biolabs), 2 µl of 10% NP40 (New England Biolabs), 2µl of PNGase F (New England Biolabs) 
  Materials and methods 
60 
 
and MilliQ water were added to the mixture to reach a final volume of 20 µl. Samples 
were incubated for 1 hour at 37 oC and then analyzed by Western blot. 
 
Treatment with tunicamycin 
CHO cells were first transfected with plasmids encoding different variants of 
GDNF. When replacing medium after 4 hours, 5 µg/ml of tunicamycin (Sigma) were 
added. After two days medium was collected and cell lysates were made, and samples 
from both were characterized by Western blot analysis. 
 
Cell lysates 
60 mm plates 
Lysis buffer was prepared on ice as follows: 
 1 ml IP medium (TBS, 10% glycerol, 1% Triton X-100, 1% Nonidet P-40, 2 mM 
EDTA)/plate  
 1 mini EDTA free tablet/10 ml of IP medium (proteinase inhibitor, from Roche) 
Medium was removed from plates and 1 ml of cold lysis buffer was added. The 
plates were then put 10 minutes on ice before performing the lysis. The lysates were 
then added to an eppendorf tube. It was vortexed and put back in ice for another 10 
minutes. The tubes were the vortexed again ad centrifuged at 17000 g for 5 minutes and 
the supernatant was moved to another eppendorf tube. 
   
24-well plate 
Lysis buffer was prepared in ice as follows: 
 125 µl IP medium (TBS, 10% glycerol, 1% Triton X-100, 1% Nonidet P-40, 2 mM 
EDTA)/well  
 ½ mini EDTA free tablet/3 ml of IP medium (proteinase inhibitor, from Roche) 
Medium was removed from plates and 125 µl of cold lysis buffer were added. The 
plates were then put 10 minutes on ice before performing the lysis. The lysates were 
then added to an eppendorf tube. It was vortexed and put back in ice for another 10 
minutes. The tubes were the vortexed again ad centrifuged at 17000 g for 5 minutes and 
the supernatant was moved to another eppendorf tube. 
 
RET phosphorylation assay 
This method is used to measure RET phosphorylation inducing capacity of differ-
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ent molecules. MG87-RET cells were first transfected with plasmids encoding GFRα re-
ceptors and later subjected to starvation, induction and lysis before immunoprecipita-
tion took place. 
 
Starvation 
Old medium was removed from 60 mm plates and cells were incubated 4 hours 
with 4.0 ml of DMEM. 
 
Induction 
DMEM was substituted with medium from CHO cells transfected two days earlier 
with plasmids encoding GDNF variants. The medium was diluted 1:2 in DMEM and the 
cells were incubated for 10 minutes at 37 oC. When E. coli GDNF, ARTN or PSPN were 
needed, the commercial molecules (GDNF from ProSpec – Tany TechnoGene Ltd., ARTN 
and PSPN from PreproTech) were used, diluting them into DMEM for a final concentration 
of 100 ng/ml. 
 
Lysis 
Lysis of cell was made as described above (see Cell lysis section). To preserve RET 
phosphorylation Na3VO4 1 mM was added to the lysis medium, since it is a phosphatase 
inhibitor. 
 
Immunoprecipitation 
5 µl of anti-RET Santa Cruz C-20 antibody were added to the samples and they 
were put on rotation at +4 oC for 1.5 hours. 
Protein G Sepharose (Amersham Biosciences) was first equilibrated washing it 
three times with 1 ml of Dulbecco + 0.2 % BSA before adding IP medium (TBS, 10% glyce-
rol, 1% Triton X-100, 1% Nonidet P-40, 2 mM EDTA). Samples were then added to the Pro-
tein G Sepharose and put back on rotation O/N at +4 oC. 
Samples were centrifuged and pellet was then analyzed by Western blot analysis. 
 
Western blot 
Detection conditions 
Samples were boiled in the presence of Laemmli buffer for 5 minutes, then run on 
the gel (at a constant current of 24 mA) before transferring them on the nitrocellulose 
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membrane (Amersham Biosciences) with a constant voltage of 100 volts for 1 hour. The 
membrane was then blocked in 3% milk in TBS-T (TBS, 10% Tween-20) for 30 minutes be-
fore staining with the primary antibodies diluted in the same solution (45 minutes). The 
membrane was then washed in TBS-T for 30 minutes, stained with secondary antibodies 
diluted in 3% milk in TBS-T (30 minutes) and then washed again in TBS-T for other 30 
minutes. Antibody staining was then detected using the ECL kit (Thermo Scientific). 
For FLAG tag detection the protocol was as follows: blocking was performed in 5% 
milk in TBS-T (TBS, 10% Tween-20) for 1 hour before staining with the primary antibodies 
diluted in the same solution (30 minutes). The membrane was then washed in TBS-T for 
5 minutes, stained with secondary antibodies diluted in 3% milk in TBS-T (30 minutes) 
and then washed again in TBS-T for 45 minutes. When M1 antibody was used, CaCl2 1 mM 
was added to all the solutions, since this antibody is calcium-dependent. 
 
Antibodies 
GDNF detection 
Gel: 15% 
Primary antibody: anti-GDNF Santa Cruz SC328 D-20, diluted 1:500 (made in rabbit) 
Secondary antibody: donkey F(ab′)2 anti-rabbit (GE Healthcare), diluted 1:3000 
 
FLAG tag detection 
Gel: 15% 
Primary antibody: anti-FLAG tag M1 Sigma-Aldrich F3040, 10 µg/ml (made in mouse) 
Secondary antibody: polyclonal goat anti-mouse (DAKO), diluted 1:1000 
or 
Primary antibody: anti-FLAG tag M2 Sigma-Aldrich F3165, 10 µg/ml (made in mouse) 
Secondary antibody: polyclonal goat anti-mouse (DAKO), diluted 1:1000 
 
RET detection 
Gel: 8% 
Primary antibody: anti-phosphorylated tyrosine Upstate 4G10, diluted 1:1500 (made 
in mouse) 
Secondary antibody: polyclonal goat anti-mouse (DAKO), diluted 1:3000 
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Phosphorylated RET detection 
Gel: 8% 
Primary antibody: anti-RET Santa Cruz C-20, diluted 1:500 (made in goat) 
Secondary antibody: polyclonal rabbit anti-goat (DAKO), diluted 1:1500 
 
Stripping 
When stripping was needed, the membrane was incubated for 30 minutes at 55 oC 
in a stripping solution (100 mM β-mercaptoethanol, 2% SDS, 62.5 mM Tris-HCl pH 6.7), 
washed in TBS-T at room temperature for 1-2 hours, and blocked again before staining it 
with the new antibody. 
 
Treatment with commercial furin 
Culture medium used to grow CHO cells transfected with plasmids encoding the 
different GDNF variants contains CaCl2 1.8 mM. Manufacturer’s instructions are that this 
digestion has to be performed using  CaCl2 1 mM, so 14 µl of medium were diluted in or-
der to reach this concentration. Then HEPES pH 7.5 100 mM, Triton X-100 0.5%, 2-
mercaptoethanol 1 mM and 2 units (1 µl) of commercial furin (New England Biolabs) 
were added, for a final volume of 25 µl.  
The reaction was carried out for at least two hours at room temperature before 
collecting the samples for Western blot. 
 
Incubation of GDNF at 37 oC 
Medium from CHO cells transfected with plasmids encoding GDNF variants was 
collected after one, two or three days from transfection and incubated at 37 oC. Also 
GDNF produced in E. coli cells was used, diluting it to a final concentration of 0.5 µg/ml 
in medium from CHO cells transfected with plasmids encoding GFP. Samples were col-
lected and boiled for 5 minutes in the presence of Laemmli buffer at the very beginning 
of the incubation and then after 2 and 8 hours and then analyzed by Western blot. 
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Computational analysis 
  Results 
66 
 
Figure 20. A. Alignment of GDNF sequences from differ-
ent species. Sequences marked with (F) are fragments. 
These sequences are homologues of human GDNF accord-
ing to NCBI-BLAST2. ELM didn’t return any results about 
secondary structures of GDNF in D. rerio, C. carpio and T. 
nigrovirids, so they have been obtained from homology 
with the other sequences. 
B. Cladogram of sequences, drawn by ClustalW2 on EBI 
website. 
Figure 21. Alignment of human GFL sequences. 
 
In both cases alignments have been made using ClustalW2 
on EBI website. Prediction of signal peptide, prosequence 
and furin cleavage sites was made with ProP, prediction 
of N-glycosylated sequences was made with NetNGlyc, 
and all the other predictions were made using ELM, on 
ExPASy website. 
 
AAA = signal peptide BBB = propeptide sequence  
CCC = α-helix DDD = β-strand EEE = 310-helix 
 
C = residue forming the cysteine-knot. Residues with the 
same symbol form a disulphide bridge. Cys178 of GDNF 
(in human, and the equivalent ones in other sequences) 
forms a S-S link with the corresponding residue on the 
other monomer, stabilizing the dimer. 
 
FFF = residues involved in GFRα1 binding (human GDNF 
only) 
 
GGG = sequences predicted to be N-glycosylated 
It must be noticed that G. gallus and N. nippon have one 
more glycosylation site, while T. nigroviridis has one less. 
 
red background = cleavage site 
Symbols refer to furin cleavage sites: a slash corresponds 
to p > threshold, while other symbols correspond to p < 
threshold but still high: 
in Figure 20A: < : p = 0.488  > : p = 0.421 ~ : p = 0.481    
* : p = 0.368  ^ : p = 0.454  @ : p = 0.353 
in Figure 21: @ : p = 0.469  + : p = 0.473  ^ : p = 0.439    
* : p = 0.418  
 
Superscript numbers indicate cleavage sites of other en-
zymes: 1 = nardilysine 2 = NEC1/NEC2 3 = PC7  
a yellow background corresponds to a neutral prediction, 
a green background to a sparse/smart filtered motif. 
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 The results show that GDNF molecule is very well conserved among different spe-
cies (see Figure 20). Prediction of α-helices, β-strands, N-linked glycosylation and pro-
teinase (especially furin and nardilysine) cleavage sites is conserved in all mammals, 
while there are some differences in birds and more variability within the fish sequences. 
The two predicted N-glycosylation sites in mammals could be respectively important for 
receptor binding specificity and stability.  
The more N-terminal putative N-glycosylation site is in fact on the top of the first 
finger that if glycosylated would be bigger than the corresponding finger of the other 
GFLs (that are not predicted to be glycosylated, see Figure 20), thus GDNF could fit (and 
consequently signal) only in the bigger “pocket” of GFRα1 and not in the ones of the 
other GFRαs, while other molecules with smaller fingers, such as neurturin, could fit not 
only in their proper receptor but also in GFRα1. 
 The other putative N-glycosylation site could instead protect GDNF from cleavage. 
It is in fact near a putative furin cleavage site conserved in human, macaque, mouse and 
rat and has a high probability of being cleaved in other mammals, birds and frog (see 
Figure 20). Moreover, there is also a nardilysine cleavage site next to this sequence that 
is conserved in all mammals. 
 The furin site is predicted to be in the same region also in NRTN and ARTN (but 
not PSPN, which is however the most divergent member of the family, see Figure 21). In 
fact, in GDNF and NRTN this site is predicted to be located after the α-helix, while in 
ARTN it would be before it. In all cases, however, this site is located after the first three 
cysteines (which form intramonomeric S-S bridges) and before the fourth (the one that 
forms disulphide bonds between the two monomers), so it could be responsible for the 
stability of the dimer. Moreover, the α-helix is protruding from the molecule (see Figure 
11), so this putative cleavage site is exposed and could be easily cleaved by furin. 
 
Glycosylation of GDNF 
Glycosylation of GDNF was studied using mutants obtained with the PCR 
mutagenesis method. The sequence of wild type GDNF was modified in order to obtain 
variants with mutations on the first predicted N-glycosylation site, on the second, or on 
both of them. CHO cells were then transfected with plasmids encoding these constructs. 
 
Treatment with PNGase F 
PNGase F is an enzyme obtained from F. meningosepticum that hydrolyzes aspar-
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Figure 23. Tunicamycin molecule. It is com-
posed of an uracil group bound to tunicamine, a 
disaccharide where the first sugar resembles 
ribose. Tunicamine is linked to a fatty acid 
chain and GlcNAc. 
agine-linked glycans deaminating asparagine to aspar-
tic acid. The only requirement is that the asparagine 
residue carrying the oligosaccharide has both the α-
amino and carboxyl groups involved in peptide link-
age.204 
Treatment with PNGase F could also be useful 
to confirm results obtained with tunicamycin since 
treatment with the antibiotics inhibits glycosylation of 
all proteins in the cells, and could affect the results 
by interfering with other cellular processes not di-
rectly involved in GDNF processing (cells treated with 
tunicamycin are stuck in G1 phase). 
 Result in Figure 22 shows that GDNF is glycosy-
lated, since when treated with PNGase F it is possible 
to observe a shifting of the bands. 
 
Treatment with tunicamycin 
Tunicamycin is an inhibitor of N-linked glycosylation that acts blocking the reac-
tion of UDP-GlcNAc and dolichol phosphate in 
the first step of glycoprotein synthesis, thus 
blocking synthesis of all N-linked glycoproteins 
in the cell. This molecule acts as a tight binding 
competitor inhibitor, because it is composed of 
uridine bound to tunicamine, thus resembling 
the donor sugar (see Figure 23). The result of 
this inhibition is that the enzyme GlcNAc phos-
photransferase is not able to transfer GlcNAc-1-
P from UDP-GlcNAc to dolichol phosphate and 
cells treated are blocked in G1 phase.205 
Cells transfected with plasmids encoding 
GDNF variants were incubated for two days in the presence or absence of 5 µg/ml of tu-
nicamycin, then media were collected and lysates were made and analyzed by Western 
                                                 
204 Tarentino AL. et al., Deglycosylation of asparagine-linked glycans by peptide:N-glycosidase F, Bioche-
mistry (1985) 24(17):4665-71 
205 Varki A. et al., Essentials of Glycobiology, Cold Spring Harbor Laboratory Press, 1999 
Figure 22. Effects of PNGase F 
on GDNF. When the molecule is 
treated with PNGase F it is pos-
sible to detect a shift in the 
banding pattern, confirming 
that GDNF molecule is glycosy-
lated, as already reported in 
literature. 
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blot (see Figure 24). 
The results show that human GDNF is glycosylated on the first predicted site, but 
not on the second. Moreover it is possible to detect a difference between the amounts 
of GDNF in the media that is bigger than the one between its intracellular quantities. 
This probably means that lack of glycosylation affects processing and secretion more 
than production of GDNF. 
 
GDNF variants: size comparison 
In Figure 25 it is possible to see that mutants on the first glycosylation site run 
more than wild type GDNF, because they lack glycosylation, but still they run less than 
commercial GDNF. This is a recombinant molecule without prosequence produced in E. 
coli (and thus unglycosylated), so the difference in size could be explained hypothesizing 
that the mutant on the first glycosylation site is secreted in its pro-form. 
 
Figure 24. Effects of tu-
nicamycin on different 
GDNF variants. The addi-
tion of tunicamycin has a 
clear effect on wild type 
processing, meaning that 
the molecule is glycosy-
lated (as already reported 
in literature), but no dif-
ferences are visible when 
comparing this molecule 
with the mutant on the 
second glycosylation site, 
meaning that this is not in 
use. A clear difference is 
instead visible when com-
paring wild type GDNF 
and the mutant on the 
first glycosylation site, 
which looks very similar 
to   GDNF    treated   with  
tunicamycin. The variant with mutation of both sites has the same banding pattern as this latter mutant, confirm-
ing that the first but not the second glycosylation site is in use. 
The experiment was performed both in the media (since GDNF is a secreted molecule) and in the lysates, where 
similar observations about intracellular GDNF can be made. 
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In Figure 26 it is possible to compare the sizes of wild type GDNF and the unglyco-
sylated variants. The difference between the two mutants is caused by the absence of 
the prosequence in the second one. The difference between the latter mutant and E. 
coli GDNF is instead caused by a flag-tag and a linker sequence (see Figure 18) present 
in the mutant I made. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. Comparison of sizes of different 
GDNF variants. It is possible to notice that 
the mutant on the first glycosylation site and 
the one on both predicted glycosylation sites 
are lighter than wild type GDNF and the mu-
tant on the second predicted glycosylation 
site, but heavier than commercial GDNF 
which is unglycosylated as well, but does not 
have the prosequence. 
Cells were cotransfected with plasmids en-
coding RET, to prove that differences in the 
amount of GDNF in the media are not caused 
by a different transfection efficacy. 
 
Figure 26. Comparison of sizes of different 
GDNF variants. The new GDNF variant with 
mutation of the first glycosylation site and 
without prosequence runs more than the 
mutant on the first glycosylation site, but 
still less than commercial GDNF, because of 
the addition of a FLAG-tag and a linker se-
quence in the mutated molecule. 
Cells were cotransfected with plasmids en-
coding RET, to prove that differences in the 
amount of GDNF in the media are not 
caused by a different transfection efficacy. 
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Specificity for α receptors 
 GDNF signalling occurs through RET which becomes phosphorylated when a GFL 
binds to its GFRα coreceptor in the GFL-GFRα-RET complex. A preliminary assay to de-
termine whether a GDNF variant can start or not this signalling is thus to examine RET 
phosphorylation. 
 
Mutant on the 1st glycosylation site with prosequence 
 Initially, mutant on the first glycosylation site was used for this experiment. Media 
from CHO cells transfected with plasmids encoding GFP, wild type GDNF or the variant 
with mutation on the first glycosylation site were collected, diluted 1:2 in DMEM and 
then used to induce RET phosphorylation on MG87-RET cells transfected with plasmids 
encoding GFP, GFRα1 or GFRα2. After cell lysis, RET was immunoprecipitated and then 
analyzed by Western blot, staining both phospho-RET and RET (see Figure 27). 
 The results show that this GDNF variant does not activate RET through GFRα2, but 
the receptor is phosphorylated when cells express GFRα1, even if less than in the pres-
ence of wild type GDNF. 
 This could be caused by the fact that this GDNF variant is secreted mainly in its 
pro-form (see Figures 25 and 26), by the lower amount of GDNF in the medium if com-
pared to wild type (see Figures 25 and 26) or by a lower stability of the molecule caused 
by the absence of N-linked glycosylation. 
 
Mutant on the 1st glycosylation site without prosequence 
 To investigate if the reduced phosphorylation of RET induced by the GDNF variant 
Figure 27. Phosphorylation of RET induced with wild type GDNF or the mutant on the glycosylation site on cells 
transfected with plasmids encoding GFRα1 or GFRα2. Controls were made using cells transfected with plasmids 
encoding GFP and induced with GDNF variants, and cells transfected with plasmids encoding GFRα receptors but 
without using GDNF for induction. 
  Results 
72 
 
with a mutated N-glycosylation site is due to the fact that this is secreted mainly as 
proGDNF, a new GDNF variant was used. This is mutated on the first glycosylation site as 
well, but lacks the prosequence. 
 
α1 compared with α2 
 Media from CHO cells transfected with plasmids encoding GFP, wild type GDNF or 
the variant with mutation on the first glycosylation site but without prosequence were 
collected, diluted 1:2 in DMEM and then used to induce RET phosphorylation on MG87-
RET cells transfected with plasmids encoding GFP, GFRα1 or GFRα2. After cell lysis, RET 
was immunoprecipitated and then analyzed by Western blot, staining both phospho-RET 
and RET (see Figure 28). 
 
 The results show that this mutant activates RET both through GFRα1 and GFRα2. 
There are no significant differences between the activity of wild type GDNF and the one 
of the mutant, and it is also possible to notice that RET activation induced by both 
molecules is higher when occurring through GFRα1. This lower activation of RET occur-
ring when GDNF signals through GFRα2 is in accordance with literature. 
 
 
 
 
 
Figure 28. Phosphorylation of RET induced with wild type GDNF or the mutant on the glycosylation site without 
prosequence on cells transfected with plasmids encoding GFRα1 or GFRα2. Controls were made using cells 
transfected with plasmids encoding GFP and induced with GDNF variants, and cells transfected with plasmids 
encoding GFRα receptors but without using GDNF for induction. 
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Figure 29. Phosphoryla-
tion of RET induced with 
wild type GDNF or the 
mutant on the glycosyla-
tion site without prose-
quence on cells trans-
fected with GFRα3. Con-
trols were made using 
cells transfected with 
plasmids encoding GFP 
and induced with GDNF 
variants, cells transfected 
with plasmids encoding 
GFRα receptors but with-
out using GDNF for induc-
tion, and cells transfected 
with plasmids encoding 
GFRα3 and induced with 
ARTN. 
α1 compared with α3 
 Media from CHO cells transfected with plasmids encoding GFP, wild type GDNF or 
the variant with mutation on the first glycosylation site but without prosequence were 
collected, diluted 1:2 in DMEM and then used to induce RET phosphorylation on MG87-
RET cells transfected with plasmids encoding GFP, GFRα1 or GFRα3. Also ARTN was used 
for the induction. After cell lysis, RET was immunoprecipitated and then analyzed by 
Western blot, staining both phospho-RET and RET (see Figure 29). 
 The results show that this mutant can still activate RET through GFRα1, but it is 
not able to activate the receptor through GFRα3, while ARTN does (showing that the 
coreceptor is working). 
 
α1 compared with α4 
 Media from CHO cells transfected with plasmids encoding GFP, wild type GDNF or 
the variant with mutation on the first glycosylation site but without prosequence were 
collected, diluted 1:2 in DMEM and then used to induce RET phosphorylation on MG87-
RET cells transfected with plasmids encoding GFP, GFRα1 or GFRα4. Also PSPN was used 
for the induction. After cell lysis, RET was immunoprecipitated and then analyzed by 
Western blot, staining both phospho-RET and RET (see Figure 30). 
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 The result shows that this mutant can still activate RET through GFRα1, but it 
does not activate the receptor through GFRα4, while PSPN does (showing that the core-
ceptor is working). 
 
Stability of GDNF 
Stability at 37 oC 
To see whether results from Figure 27 could be caused by a lower stability of the 
mutant on the first glycosylation site, media from CHO cells transfected with plasmids 
encoding GDNF variants were collected and incubated at 37 oC. Samples were collected 
at the beginning of incubation and after 2 and 8 hours. Also E. coli GDNF diluted in me-
dium from CHO cells transfected with plasmids encoding GFP was used (See Figure 31). 
Figure 30. Phosphorylation of RET induced with wild type GDNF or the mutant on the glycosylation site without 
prosequence on cells transfected with plasmids encoding GFRα4. Controls were made using cells transfected with 
plasmids encoding GFP and induced with GDNF variants, cells transfected with plasmids encoding GFRα receptors 
but without using GDNF for induction, and cells transfected with plasmids encoding GFRα4 and induced with 
PSPN. 
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 The results show that wild type GDNF remains stable for hours, while E. coli GDNF 
is not present after 8 hours. The two GDNF variants with a mutated N-glycosylation site 
are quite stable from the second day after transfection, but it is difficult to compare 
their stability with the one of wild type GDNF because of the differences in the amounts 
in the media. However, the mutant on the first glycosylation site with prosequence is as 
stable as the mutant without prosequence, so the results of RET phosphorylation assays 
(see Figure 27) are not due to a lower stability. 
 
Furin cleavage 
Furin belongs to a group of proteolytic enzymes homologous to kexin, a protease 
from yeast. These enzymes are called subtilisin-like proprotein converetases (SPCs) be-
cause their catalytic domain is very similar to the one of subtilisin, a bacterial serine 
protease. The role of these enzymes is very important because they are able to cleave 
Figure 31. Stability of different GDNF variants at 1, 2 or 3 days after transfection of CHO cells. Commercial GDNF 
was diluted in medium collected from cells transfected with plasmids encoding GFP 1, 2 and 3 days after trans-
fection. In RET phosphorylation assays with these GDNF variants, media for induction were collected two days 
after transfection, so especially stability at day 2 has to be considered. 
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prosequences from proteins turning them into biologically active molecules. Furin also 
has a prodomain, followed by a catalytic module conserved among SPCs and a so-called 
P-domain which has a regulatory function and stabilizes the catalytic domain. Furin re-
quires the N-terminal pro-domain for its correct folding in the ER; after that the se-
quence is cleaved, but it remains non-covalently attached to the protein which is fully 
activated only when it reaches the trans-Golgi network. The sequence recognized by this 
enzyme is Arg-X-[Lys/Arg]-Arg-X (where X can be any amino acid) and is cleaved between 
the fourth and the fifth amino acid.206 
According to analysis performed with ELM, human GDNF has two sequences that 
can be recognized and cleaved by furin: the first one is 74RLRRS78 and the second one 
165RNRRL169 (see Figures 17 and 18). The first sequence is where the prosequence is 
cut off from GDNF molecule, while the second localizes just C-terminal to the α-helix 
and is the site that was mutated in this study. 
 
Coexpression with furin 
CHO cells in a 60 mm plate were cotransfected with plasmids encoding GFP, solu-
ble furin or full-length furin and plasmids encoding GDNF variants. Samples were col-
lected one and two days after cotransfection and analyzed by Western blot (see Figure 
32). 
 
The results in show that coexpression with either full-length or soluble furin af-
fects the two upper bands (the ones that are thought to correspond respectively to gly-
cosylated and unglycosylated proGDNF). No further smaller bands are observed when 
wild type GDNF is coexpressed with furin and no differences are visible between wild 
type GDNF and the mutant on the furin cleavage site. This result leads to the conclusion 
                                                 
206 Steiner DF., The proprotein convertases, Curr Opin Chem Biol. (1998) 2(1):31-9 
Figure 32. Comparison between GDNF variants coexpressed with plasmids encoding GFP or furin variants. Full-
length furin has a transmembrane domain and localizes especially into the trans-Golgi network, but also in en-
dosomes and on the cellular membrane, while soluble furin is a secreted variant without the transmembrane do-
main. 
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that during secretion this site is not in use. 
 
Treatment with commercial furin 
For this experiment medium collected from CHO cells transfected two days earlier 
with plasmids encoding either wild type GDNF or the variant with the mutation of the 
furin cleavage site were digested using commercial furin (New England Biolabs), accord-
ing to manufacturer’s instructions. 
Samples were collected at the beginning of the reaction and after 2 and 8 hours, 
and then analyzed by Western blot (see Figure 33). 
 
 
 
 
 
The result shows no differences between the cleavage of wild type GDNF and the 
mutant, thus furin cleavage site seems to be not in use. 
 
Activity of GDNF variant with mutation on the furin site 
Affinity for GFRα1 
 As shown in Figure 34, the amount of wild type GDNF in the 
medium is the same as the one of the mutant on the furin cleavage 
site, so this mutation is not affecting the production of the mole-
cule. 
 
 Media from CHO cells transfected with plasmids encoding 
GFP, wild type GDNF or the variant with mutation on the furin site 
were collected, diluted 1:2 in DMEM and then used to induce RET 
phosphorylation on MG87-RET cells transfected with plasmids en-
coding GFP or GFRα1. After cell lysis, RET was immunoprecipitated 
and then analyzed by Western blot, staining both phospho-RET and 
RET (see Figure 35). 
Figure 33. Digestion with commercial 
furin of wild type GDNF and the mu-
tant on the predicted glycosylation 
site. 
Figure 34.  Amount 
of wild type GDNF 
and mutant on the 
furin cleavage site in 
media and lysates.  
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The results show that this mutant can activate RET through GFRα1, and this acti-
vation is at the same level of the one induced by wild type GDNF. 
 
Duration of RET phosphorylation 
 For this experiment MG87-RET cells were starved overnight and the next morning 
the induction was made using wild type GDNF, the variant with mutation of the furin site 
or commercial GDNF (ProSpec – Tany TechnoGene Ltd.). Lysates were made after 10 min-
utes, 2, 5 or 8 hours of induction and immunoprecipitated and analyzed as described in 
Materials and methods (see Figure 36). 
 
 Results show that the duration of phosphorylation induced by wild type GDNF is 
the same as the one induced by the mutant on the furin cleavage site. 
 
Interpretation of banding pattern 
GDNF is first produced as a prepromolecule, from which are cleaved off first the 
pre- and then the prosequence. Its banding pattern when produced in CHO cells is quite 
Figure 36. Phosphorylation of RET induced with wild type GDNF, the mutant on the furin cleavage site or commer-
cial GDNF on cells transfected with plasmids encoding GFRα1. Control was made using cells transfected with plas-
mids encoding GFRα1 where no induction was performed. Lysates were then made after 10 minutes and 2, 5 and 8 
hours. 
Figure 35.  Phosphorylation of 
RET induced with wild type GDNF 
or the mutant on the furin cleav-
age site on cells transfected with 
plasmids encoding GFRα1. Con-
trols were made using cells trans-
fected with plasmids encoding 
GFP and induced with GDNF vari-
ants, and cells transfected with 
plasmids encoding GFRα1 recep-
tors but without using GDNF for 
induction. 
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characteristic, even if small variations in the strength of the bands are possible depend-
ing on the conditions. 
Until now, only one band had been sequenced and that contained both mature 
GDNF and a shorter form lacking the first six amino acids. At the present time it is still 
not known whether this second form is produced thanks to the cleavage by an unknown 
enzyme or is coming out after the cleavage of the prosequence and the “chewing” of 
these first six residues. 
The GDNF molecule used in this work is a bit longer than human GDNF, since it has 
a flag-tag and a linker sequence immediately after the prosequence (see Figure 18), 
thus it was possible to use different anti-FLAG antibodies to detect the protein after 
Western blot (see Figure 37). The anti-FLAG M1 antibody recognizes the flag tag only 
when it is in the N-terminus of the protein, while the anti-FLAG M2 antibody can recog-
nize it anywhere, even if its efficacy was lower when the flag-tag was located into an 
internal site. 
 
 
 
 
 
 
The result in Figure 37 shows that the strong upper band in wild type GDNF (1) 
Figure 37. Interpreta-
tion of GDNF binding 
pattern. 
 Wild type GDNF from 
different CHO cells, 
wild type GDNF 
treated with PNGase F, 
the mutants on the 
first glycosylation site 
(both the one with and 
the one without the 
prosequence), a GDNF 
variant without prose-
quence and commer-
cial GDNF were ana-
lyzed. The filter was 
first stained with M1 
antibodies recognizing 
the FLAG-tag only 
when located in the N-
terminus, then with M2 
antibodies, recognizing 
this tag anywhere in 
the protein sequence, 
and then with anti-
GDNF antibodies. 
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corresponds to glycosylated proGDNF (since it is recognized by M2 but not by M1), and 
that the upper band in the mutant on the first glycosylation site and in wild type GDNF 
treated with PNGase F (*) corresponds to the unglycosylated proGDNF (it is recognized 
by M2 but not by M1 and runs more than the glycosylated form). The strong upper band 
visible in the lane where wild type GDNF without prosequence was running (3) is recog-
nized by both antibodies, so it corresponds to the glycosylated form of mature GDNF. 
This means that the middle strong band in wild type GDNF (3*) corresponds to both un-
glycosylated proGDNF and mature glycosylated GDNF. The band visible when running the 
GDNF variant which lacks both the first glycosylation site and the prosequence (5) corre-
sponds to the unglycosylated mature form. The weaker bands above (4) and under (6) 
this one (more easily visible in wild type GDNF without prosequence) are not stained by 
any of the antiFLAG antibodies, so these probably correspond to the shorter form of 
GDNF (the upper one being the glycosylated form and the lower one being the unglyco-
sylated). It remains more difficult to explain the band between the glycosylated and the 
unglycosylated proGDNF (2), since it seems that no one of the antiFLAG antibodies rec-
ognizes it. A possible explanation is that the affinity of M2 for the flag-tag is lower when 
its sequence is not at the N-terminus, and consequently the signal could be not strong 
enough to be detectable. Since there are some cleavage sites in the prosequence (see 
Figure 17) this band could correspond to glycosylated proGDNF that has been cleaved 
somewhere along the prosequence by nardilysine, NEC1/NEC2 or PC7. Commercial GDNF 
(x) is not glycosylated and does not have the prosequence and the flag tag, so it is rec-
ognized only by antibodies antiGDNF. 
However, to really prove this analysis, the bands should be sequenced. 
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Glycosylation of GDNF 
 
From the first time GDNF was purified (Lin et al., 1993) it was already known that 
it was glycosylated, but nothing was known about the site where this glycosylation is oc-
curring or its role. 
From the computational analysis I performed it is possible to notice that the first 
predicted glycosylation site (the one on the first finger) is conserved in all animals, 
while the second (the one near the predicted furin cleavage site) can be found in almost 
every species except Tetraodon nigroviridis. It is also possible to notice that birds have 
one more predicted glycosylation site. However the mutagenic PCR I made on human 
GDNF (which does not have the third site present in birds) showed that only the first site 
is in use. 
Since this site is located on the first finger, close to some residues that are impor-
tant for GFRα1 binding (Parkash et al., 2008), our hypothesis was that its mutation could 
affect the specificity of GDNF for its receptor. Indeed, my RET phosphorylation assays 
show a lower level of phosphorylation of RET when the induction is made with the mu-
tant on the first glycosylation site (see Figure 27). 
Moreover, this molecule is processed somehow differently from the wild type, 
since the banding pattern is not just shifted (as it should result from the fact that, being 
unglycosylated, the molecule is lighter) but it also looks different from the one of wild 
type GDNF and the amount of GDNF in the medium is lower (see Figures 24, 25 and 26). 
This molecule also is also heavier than commercial GDNF which is made in E. coli (and so 
it is not glycosylated either) and does not have the prosequence (see Figures 25 and 26).  
Consequently, the lower activation of RET could be due to a lower amount of 
GDNF in the medium, to the fact that this band is heavier than the one detected using 
commercial GDNF (and so it could be that this mutant is secreted mainly in its pro-
form), or to a lower stability of GDNF. 
To investigate further on this matter I made another mutant on the first glycosyla-
tion site which lacks the prosequence. This GDNF variant still runs less than commercial 
GDNF (see Figure 26), but this is caused by the presence of 10 additional amino acids 
forming a flag tag and a linker (see Figure 18). The amount of this mutant in the me-
dium is even lower than the amount of the mutant with the prosequence (see Figure 
26), but the levels of activation of RET through GFRα1 and GFRα2 are the same as the 
ones obtained with wild type molecule (see Figure 28). I also tried to see whether lack 
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of glycosylation could enhance signalling through GFRα3 or GFRα4, but no difference 
with wild type was observed (see Figures 29 and 30). 
These results suggest that lack of glycosylation is not directly involved in a lower 
phosphorylation of RET, since both the mutant on the glycosylation site without prose-
quence and E. coli GDNF induce a phosphorylation which is as strong as the one induced 
by wild type. Besides, the lower levels of activation of RET induced by the mutant on 
the first glycosylation site are not due to its lower amount in the medium, since the 
amount of the mutant lacking the prosequence is even lower. 
So this result could be caused either by the fact that proGDNF is not able to acti-
vate the complex as much as mature GDNF or by a lower stability of the mutant. Wild 
type GDNF, the two mutants on the first glycosylation site and commercial GDNF were 
thus incubated for 8 hours at 37 oC 1, 2 and 3 days after transfection to test their stabil-
ity. The results show that wild type GDNF is more stable than commercial GDNF, while it 
is difficult to compare the two mutants with wild type GDNF because of their lower 
amount in the medium. However, it is possible to compare the two mutants together and 
to see that their stability is the same (see Figure 31).  
Consequently it is possible to conclude that when the first glycosylation site is 
mutated GDNF is secreted mainly in its pro-form which fails to activate the GFRα-RET 
complex at the same levels as mature GDNF. 
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Furin cleavage site 
 
GDNF has two predicted furin cleavage sites. One is after the prosequence and is 
needed for the maturation of RET, while the other predicted site is right after the α-
helix.  
Computational analyses show that this site is conserved in human, mouse, rat and 
monkey, and has a high probability of being in use also in other mammals, birds and X. 
laevis (see Figure 20A). Moreover, all other GFLs (except PSPN which is the most diver-
gent member of the family) are predicted to have a furin cleavage site in the same re-
gion: in NRTN the site is predicted to be after the α-helix (as in GDNF), while in ARTN it 
could be before the helix (see Figure 21). Despite this difference, the important thing is 
that the predicted site is after the three cysteines that form the intramonomeric bridges 
and before the one involved in the S-S bridge between the monomers (see Figure 20) 
and so it could be related to the stability of the dimer. Moreover, it is likely that this site 
is in use because the α-helix is protruding from the molecule and so this site could be 
exposed to furin cleavage. 
Immediately before the furin cleavage site, there is also a predicted nardilysine 
cleavage site which is, still according to computational analysis, conserved amongst 
mammals (see Figure 20A). The mutant was made in such a way that not only the pre-
dicted furin cleavage site is mutated, but also the nardilysine cleavage site becomes un-
cleavable. 
The amount of this GDNF variant in both the medium and the lysates is the same 
as wild type (see Figure 34). 
To see whether this site is in use or not, I performed both cotransfections with 
furin (see Figure 32) and treatments with commercial furin (see Figure 33). The results 
of both these kinds of experiments show that probably this site is not in use during se-
cretion (when full-length furin or the soluble mutant should act), since furin seems to 
affect only the two upper bands, which are thought to correspond to proGDNF (the up-
per one corresponding to the glycosylated form, and the lower to the unglycosylated 
molecule). Moreover, no differences are visible between wild type GDNF and the mutant 
on the putative furin cleavage site (see Figures 32 and 33). As said, the first furin cleav-
age site is shown to be in use instead, since the amount of the upper bands decreases in 
the presence of furin (see Figures 32 and 33). 
However, this site could also be important in other moments, not only during se-
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cretion. For example it could happen that, when GDNF binds to GFRα-RET complex and 
activates it, cleavage by furin reduces the time during which the molecule stays in its 
dimeric form (and can thus activate the receptor complex). So I performed RET phos-
phorylation assays in order to detect if the mutant can induce a higher activation of the 
complex or a longer duration of RET phosphorylation (see Figures 35 and 36). Even in 
this case, no differences between wild type GDNF and furin site mutant were observed. 
These results lead to the conclusion that at least in these conditions, this second 
predicted furin site is not in use. 
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